| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polymorphism, Single Nucleotide | 290 | 2021 | 2494 | 13.430 |
Why?
|
| Genetic Predisposition to Disease | 176 | 2021 | 2474 | 7.640 |
Why?
|
| Genome-Wide Association Study | 152 | 2022 | 1765 | 6.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 114 | 2020 | 1346 | 5.710 |
Why?
|
| Cancer Vaccines | 34 | 2025 | 170 | 5.560 |
Why?
|
| Lung Neoplasms | 76 | 2020 | 2463 | 5.190 |
Why?
|
| Antigens, Neoplasm | 34 | 2025 | 359 | 4.930 |
Why?
|
| Neoplasms | 66 | 2025 | 3248 | 4.700 |
Why?
|
| Histone-Lysine N-Methyltransferase | 29 | 2023 | 165 | 4.620 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 106 | 2016 | 701 | 4.560 |
Why?
|
| Gene Expression Profiling | 95 | 2018 | 1535 | 4.520 |
Why?
|
| Breast Neoplasms | 70 | 2022 | 3157 | 4.390 |
Why?
|
| Humans | 816 | 2025 | 96105 | 4.210 |
Why?
|
| Japan | 130 | 2021 | 313 | 4.110 |
Why?
|
| Cell Line, Tumor | 166 | 2025 | 2778 | 4.040 |
Why?
|
| Immunotherapy | 24 | 2021 | 766 | 3.530 |
Why?
|
| Nuclear Proteins | 35 | 2017 | 750 | 3.250 |
Why?
|
| Receptors, Antigen, T-Cell | 21 | 2025 | 432 | 3.200 |
Why?
|
| Biomarkers, Tumor | 62 | 2022 | 1670 | 3.130 |
Why?
|
| Pharmacogenetics | 24 | 2024 | 456 | 3.090 |
Why?
|
| Case-Control Studies | 138 | 2021 | 1957 | 3.040 |
Why?
|
| Cell Proliferation | 64 | 2020 | 1753 | 3.010 |
Why?
|
| Genotype | 120 | 2021 | 1881 | 2.960 |
Why?
|
| Genome, Human | 48 | 2014 | 824 | 2.840 |
Why?
|
| Female | 385 | 2025 | 50028 | 2.810 |
Why?
|
| Neoplasm Proteins | 30 | 2018 | 553 | 2.760 |
Why?
|
| Cytochrome P-450 CYP2D6 | 17 | 2016 | 52 | 2.740 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 10 | 2024 | 157 | 2.650 |
Why?
|
| Tumor Suppressor Protein p53 | 28 | 2020 | 465 | 2.640 |
Why?
|
| Antineoplastic Agents | 44 | 2021 | 2418 | 2.630 |
Why?
|
| Cell Cycle Proteins | 26 | 2017 | 412 | 2.610 |
Why?
|
| Middle Aged | 279 | 2025 | 28368 | 2.610 |
Why?
|
| Stomach Neoplasms | 21 | 2020 | 310 | 2.600 |
Why?
|
| Precision Medicine | 12 | 2021 | 454 | 2.590 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 84 | 2013 | 897 | 2.570 |
Why?
|
| Aged | 230 | 2025 | 20968 | 2.560 |
Why?
|
| Tamoxifen | 18 | 2019 | 171 | 2.560 |
Why?
|
| Genetic Loci | 35 | 2021 | 260 | 2.430 |
Why?
|
| Male | 334 | 2025 | 45863 | 2.380 |
Why?
|
| Peptides | 26 | 2025 | 671 | 2.370 |
Why?
|
| Colorectal Neoplasms | 35 | 2024 | 1069 | 2.360 |
Why?
|
| Linkage Disequilibrium | 76 | 2019 | 481 | 2.350 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2019 | 611 | 2.340 |
Why?
|
| DNA-Binding Proteins | 41 | 2018 | 1267 | 2.320 |
Why?
|
| Tumor Microenvironment | 10 | 2024 | 555 | 2.300 |
Why?
|
| Genetic Variation | 51 | 2020 | 1423 | 2.290 |
Why?
|
| Transcription Factors | 40 | 2020 | 1730 | 2.280 |
Why?
|
| Esophageal Neoplasms | 19 | 2022 | 346 | 2.240 |
Why?
|
| RNA, Small Interfering | 71 | 2019 | 563 | 2.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 33 | 2018 | 1172 | 2.200 |
Why?
|
| Carrier Proteins | 26 | 2016 | 683 | 2.110 |
Why?
|
| Urinary Bladder Neoplasms | 18 | 2018 | 382 | 2.090 |
Why?
|
| Up-Regulation | 43 | 2020 | 740 | 2.080 |
Why?
|
| Pancreatic Neoplasms | 26 | 2025 | 725 | 2.070 |
Why?
|
| Gene Frequency | 70 | 2020 | 703 | 1.990 |
Why?
|
| Polymorphism, Genetic | 32 | 2017 | 829 | 1.990 |
Why?
|
| N-Acetylgalactosaminyltransferases | 7 | 2019 | 12 | 1.980 |
Why?
|
| CD8-Positive T-Lymphocytes | 13 | 2025 | 667 | 1.940 |
Why?
|
| Lymph Nodes | 8 | 2024 | 565 | 1.900 |
Why?
|
| Alleles | 59 | 2018 | 1157 | 1.890 |
Why?
|
| Adult | 202 | 2025 | 28721 | 1.880 |
Why?
|
| Head and Neck Neoplasms | 11 | 2023 | 1089 | 1.870 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 9 | 2019 | 98 | 1.870 |
Why?
|
| Haplotypes | 53 | 2013 | 650 | 1.810 |
Why?
|
| Membrane Proteins | 19 | 2016 | 1276 | 1.790 |
Why?
|
| Neoplastic Stem Cells | 6 | 2020 | 172 | 1.780 |
Why?
|
| Mutation | 42 | 2025 | 4374 | 1.710 |
Why?
|
| Antineoplastic Agents, Hormonal | 13 | 2019 | 154 | 1.690 |
Why?
|
| Carcinoma, Renal Cell | 13 | 2016 | 367 | 1.680 |
Why?
|
| Molecular Sequence Data | 70 | 2015 | 3040 | 1.680 |
Why?
|
| DNA, Complementary | 35 | 2012 | 394 | 1.670 |
Why?
|
| Carcinoma, Squamous Cell | 21 | 2017 | 1105 | 1.670 |
Why?
|
| Cell Transformation, Neoplastic | 19 | 2017 | 465 | 1.670 |
Why?
|
| Aged, 80 and over | 87 | 2020 | 7229 | 1.650 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2019 | 2642 | 1.640 |
Why?
|
| Repressor Proteins | 17 | 2020 | 447 | 1.640 |
Why?
|
| GTPase-Activating Proteins | 7 | 2020 | 68 | 1.620 |
Why?
|
| Adenocarcinoma | 27 | 2018 | 1215 | 1.620 |
Why?
|
| Histones | 17 | 2020 | 363 | 1.600 |
Why?
|
| Circulating Tumor DNA | 7 | 2025 | 76 | 1.590 |
Why?
|
| Dendritic Cells | 11 | 2025 | 541 | 1.570 |
Why?
|
| Kidney Neoplasms | 14 | 2016 | 558 | 1.570 |
Why?
|
| T-Lymphocytes, Cytotoxic | 28 | 2022 | 320 | 1.550 |
Why?
|
| Biological Specimen Banks | 18 | 2021 | 72 | 1.510 |
Why?
|
| Apoptosis | 42 | 2020 | 1756 | 1.500 |
Why?
|
| Sequence Analysis, DNA | 28 | 2020 | 910 | 1.470 |
Why?
|
| Lysine | 13 | 2020 | 190 | 1.460 |
Why?
|
| Ubiquitin-Protein Ligases | 18 | 2024 | 185 | 1.450 |
Why?
|
| Methylation | 25 | 2018 | 295 | 1.450 |
Why?
|
| Signal Transduction | 41 | 2018 | 3581 | 1.440 |
Why?
|
| Genomics | 9 | 2025 | 857 | 1.440 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 18 | 2016 | 396 | 1.440 |
Why?
|
| Chromosome Mapping | 37 | 2019 | 1083 | 1.410 |
Why?
|
| T-Lymphocytes | 13 | 2025 | 1316 | 1.410 |
Why?
|
| Carcinoma, Hepatocellular | 19 | 2018 | 426 | 1.390 |
Why?
|
| Naphthyridines | 6 | 2019 | 27 | 1.380 |
Why?
|
| Receptors, Cell Surface | 9 | 2015 | 298 | 1.380 |
Why?
|
| Liver Neoplasms | 23 | 2018 | 793 | 1.380 |
Why?
|
| Proteins | 19 | 2013 | 816 | 1.370 |
Why?
|
| Proto-Oncogene Proteins c-akt | 12 | 2016 | 367 | 1.340 |
Why?
|
| DNA | 19 | 2013 | 1333 | 1.340 |
Why?
|
| Prognosis | 62 | 2020 | 4028 | 1.320 |
Why?
|
| Epitopes, T-Lymphocyte | 9 | 2022 | 96 | 1.320 |
Why?
|
| Hepatitis C, Chronic | 17 | 2013 | 96 | 1.310 |
Why?
|
| Ovarian Neoplasms | 8 | 2020 | 801 | 1.280 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2017 | 1230 | 1.260 |
Why?
|
| Animals | 152 | 2025 | 28891 | 1.260 |
Why?
|
| Mice | 107 | 2025 | 12537 | 1.260 |
Why?
|
| Transfection | 44 | 2016 | 908 | 1.260 |
Why?
|
| High-Throughput Nucleotide Sequencing | 14 | 2025 | 540 | 1.240 |
Why?
|
| Base Sequence | 54 | 2020 | 2344 | 1.230 |
Why?
|
| Immunotherapy, Adoptive | 10 | 2025 | 277 | 1.210 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 2018 | 113 | 1.200 |
Why?
|
| Tumor Cells, Cultured | 38 | 2020 | 1049 | 1.200 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2015 | 841 | 1.190 |
Why?
|
| Protein Processing, Post-Translational | 12 | 2018 | 416 | 1.180 |
Why?
|
| Interleukins | 15 | 2013 | 134 | 1.180 |
Why?
|
| Vaccines, Subunit | 13 | 2018 | 55 | 1.170 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2015 | 303 | 1.160 |
Why?
|
| Amino Acid Sequence | 43 | 2016 | 2090 | 1.160 |
Why?
|
| Sarcoma, Synovial | 9 | 2021 | 22 | 1.150 |
Why?
|
| Arthritis, Rheumatoid | 18 | 2013 | 187 | 1.140 |
Why?
|
| Molecular Targeted Therapy | 8 | 2017 | 307 | 1.130 |
Why?
|
| Trans-Activators | 15 | 2014 | 446 | 1.130 |
Why?
|
| Epitopes | 17 | 2023 | 258 | 1.130 |
Why?
|
| Colonic Neoplasms | 16 | 2017 | 589 | 1.130 |
Why?
|
| Gene Knockdown Techniques | 16 | 2019 | 256 | 1.120 |
Why?
|
| ErbB Receptors | 8 | 2019 | 513 | 1.110 |
Why?
|
| Prostatic Neoplasms | 21 | 2024 | 1798 | 1.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 9 | 2011 | 133 | 1.070 |
Why?
|
| Receptors, G-Protein-Coupled | 13 | 2015 | 164 | 1.070 |
Why?
|
| COS Cells | 35 | 2016 | 168 | 1.070 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2025 | 644 | 1.060 |
Why?
|
| Transcription, Genetic | 25 | 2017 | 1192 | 1.050 |
Why?
|
| Immunohistochemistry | 49 | 2020 | 1828 | 1.000 |
Why?
|
| Tumor Suppressor Proteins | 17 | 2012 | 301 | 1.000 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2020 | 319 | 1.000 |
Why?
|
| Warfarin | 5 | 2013 | 107 | 0.980 |
Why?
|
| Promoter Regions, Genetic | 37 | 2019 | 996 | 0.970 |
Why?
|
| Blotting, Western | 29 | 2015 | 796 | 0.970 |
Why?
|
| HLA-A Antigens | 11 | 2022 | 40 | 0.970 |
Why?
|
| Diabetic Nephropathies | 7 | 2011 | 90 | 0.960 |
Why?
|
| Genetic Association Studies | 13 | 2021 | 301 | 0.950 |
Why?
|
| Receptors, Antigen, B-Cell | 5 | 2024 | 120 | 0.950 |
Why?
|
| Immunoglobulin Isotypes | 2 | 2018 | 33 | 0.940 |
Why?
|
| Phosphorylation | 27 | 2017 | 1157 | 0.940 |
Why?
|
| Asthma | 19 | 2016 | 1051 | 0.940 |
Why?
|
| RNA, Messenger | 50 | 2018 | 2090 | 0.930 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 6 | 2018 | 27 | 0.930 |
Why?
|
| Antiviral Agents | 17 | 2012 | 504 | 0.920 |
Why?
|
| Chromosomal Proteins, Non-Histone | 5 | 2015 | 65 | 0.920 |
Why?
|
| ATP-Binding Cassette Transporters | 8 | 2010 | 142 | 0.920 |
Why?
|
| Exome | 2 | 2016 | 141 | 0.890 |
Why?
|
| Polymerase Chain Reaction | 22 | 2011 | 930 | 0.890 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 6 | 2013 | 44 | 0.890 |
Why?
|
| Histocompatibility Antigens Class I | 6 | 2020 | 209 | 0.890 |
Why?
|
| Interferon-alpha | 11 | 2012 | 215 | 0.880 |
Why?
|
| Blotting, Northern | 25 | 2012 | 258 | 0.880 |
Why?
|
| Leukopenia | 5 | 2016 | 68 | 0.880 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2012 | 37 | 0.880 |
Why?
|
| Intracranial Aneurysm | 5 | 2016 | 206 | 0.870 |
Why?
|
| Immunotherapy, Active | 2 | 2022 | 15 | 0.870 |
Why?
|
| RNA Interference | 25 | 2017 | 385 | 0.860 |
Why?
|
| Chromosomes, Human, Pair 1 | 13 | 2014 | 102 | 0.860 |
Why?
|
| Protein Binding | 32 | 2017 | 1560 | 0.850 |
Why?
|
| Treatment Outcome | 44 | 2025 | 9175 | 0.850 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2015 | 91 | 0.850 |
Why?
|
| Glomerulonephritis, IGA | 5 | 2006 | 12 | 0.850 |
Why?
|
| DNA Methylation | 11 | 2020 | 703 | 0.840 |
Why?
|
| Chromosomes, Human, Pair 6 | 9 | 2012 | 128 | 0.840 |
Why?
|
| Protein Methyltransferases | 5 | 2018 | 15 | 0.840 |
Why?
|
| Gene Expression Regulation | 27 | 2021 | 2061 | 0.830 |
Why?
|
| Ribavirin | 15 | 2012 | 40 | 0.830 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2020 | 943 | 0.830 |
Why?
|
| Down-Regulation | 22 | 2019 | 526 | 0.830 |
Why?
|
| Quinazolines | 7 | 2016 | 216 | 0.830 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2017 | 129 | 0.820 |
Why?
|
| Anti-HIV Agents | 3 | 2011 | 199 | 0.820 |
Why?
|
| Estrogen Receptor alpha | 5 | 2020 | 155 | 0.810 |
Why?
|
| Chromosomes, Human, Pair 9 | 8 | 2018 | 80 | 0.800 |
Why?
|
| Crohn Disease | 11 | 2016 | 806 | 0.800 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 484 | 0.800 |
Why?
|
| HLA-A24 Antigen | 15 | 2025 | 21 | 0.800 |
Why?
|
| NIH 3T3 Cells | 21 | 2020 | 112 | 0.790 |
Why?
|
| Cell Nucleus | 7 | 2018 | 623 | 0.790 |
Why?
|
| HEK293 Cells | 19 | 2020 | 706 | 0.790 |
Why?
|
| Chromosomes, Human, Pair 5 | 13 | 2014 | 115 | 0.790 |
Why?
|
| Vaccination | 8 | 2020 | 311 | 0.780 |
Why?
|
| Neoplasm Staging | 17 | 2022 | 2086 | 0.780 |
Why?
|
| DNA Damage | 16 | 2017 | 392 | 0.780 |
Why?
|
| Obesity | 9 | 2012 | 1030 | 0.780 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2024 | 488 | 0.770 |
Why?
|
| Receptors, Estrogen | 11 | 2020 | 417 | 0.770 |
Why?
|
| Amino Acid Substitution | 18 | 2019 | 336 | 0.770 |
Why?
|
| Protein-Arginine N-Methyltransferases | 5 | 2015 | 22 | 0.770 |
Why?
|
| Introns | 21 | 2012 | 304 | 0.770 |
Why?
|
| Xenograft Model Antitumor Assays | 13 | 2021 | 528 | 0.760 |
Why?
|
| Frizzled Receptors | 7 | 2021 | 15 | 0.750 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 5 | 2013 | 15 | 0.740 |
Why?
|
| Lupus Erythematosus, Systemic | 9 | 2013 | 235 | 0.740 |
Why?
|
| Glycoproteins | 7 | 2011 | 233 | 0.740 |
Why?
|
| Cell Adhesion Molecules | 5 | 2009 | 176 | 0.740 |
Why?
|
| Genotyping Techniques | 5 | 2016 | 71 | 0.720 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2016 | 518 | 0.720 |
Why?
|
| Cell Cycle | 21 | 2016 | 516 | 0.720 |
Why?
|
| Hepacivirus | 15 | 2013 | 137 | 0.720 |
Why?
|
| Cell Line | 39 | 2013 | 2537 | 0.710 |
Why?
|
| Proto-Oncogene Proteins | 14 | 2012 | 684 | 0.700 |
Why?
|
| Thiophenes | 3 | 2019 | 45 | 0.690 |
Why?
|
| Cholangiocarcinoma | 7 | 2024 | 80 | 0.690 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 6 | 2021 | 50 | 0.690 |
Why?
|
| Bronchi | 5 | 2017 | 234 | 0.690 |
Why?
|
| Genetic Therapy | 5 | 2021 | 382 | 0.690 |
Why?
|
| Gene Expression | 28 | 2017 | 1320 | 0.680 |
Why?
|
| Bile Duct Neoplasms | 7 | 2024 | 91 | 0.680 |
Why?
|
| Quinolones | 3 | 2019 | 57 | 0.680 |
Why?
|
| Esophagectomy | 1 | 2022 | 92 | 0.680 |
Why?
|
| Cytoskeletal Proteins | 11 | 2011 | 227 | 0.680 |
Why?
|
| Risk Factors | 48 | 2024 | 5961 | 0.670 |
Why?
|
| Taxoids | 3 | 2016 | 131 | 0.670 |
Why?
|
| Liquid Biopsy | 5 | 2021 | 48 | 0.670 |
Why?
|
| Cell Movement | 12 | 2024 | 816 | 0.670 |
Why?
|
| DNA, Neoplasm | 10 | 2016 | 272 | 0.660 |
Why?
|
| Nevirapine | 2 | 2011 | 5 | 0.650 |
Why?
|
| Sentinel Lymph Node | 1 | 2020 | 22 | 0.650 |
Why?
|
| Immunogenetics | 2 | 2021 | 8 | 0.650 |
Why?
|
| Plasma | 1 | 2020 | 51 | 0.650 |
Why?
|
| Serum | 1 | 2020 | 25 | 0.650 |
Why?
|
| Peptide Fragments | 13 | 2018 | 477 | 0.650 |
Why?
|
| Cell Division | 12 | 2011 | 705 | 0.640 |
Why?
|
| Quantitative Trait Loci | 12 | 2021 | 632 | 0.640 |
Why?
|
| Ascites | 1 | 2020 | 57 | 0.640 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2018 | 883 | 0.640 |
Why?
|
| Fibroblasts | 8 | 2016 | 777 | 0.640 |
Why?
|
| Immunoprecipitation | 18 | 2015 | 139 | 0.630 |
Why?
|
| Databases, Genetic | 9 | 2021 | 284 | 0.630 |
Why?
|
| DNA Repair | 6 | 2014 | 376 | 0.630 |
Why?
|
| HeLa Cells | 16 | 2016 | 522 | 0.630 |
Why?
|
| DNA Primers | 24 | 2012 | 548 | 0.620 |
Why?
|
| Life Style | 6 | 2017 | 186 | 0.620 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2018 | 46 | 0.610 |
Why?
|
| Inventions | 1 | 2019 | 14 | 0.610 |
Why?
|
| Preoperative Care | 1 | 2022 | 418 | 0.600 |
Why?
|
| Testis | 8 | 2014 | 153 | 0.600 |
Why?
|
| Transcriptional Activation | 20 | 2016 | 303 | 0.600 |
Why?
|
| Disease-Free Survival | 12 | 2022 | 1196 | 0.600 |
Why?
|
| Pneumonectomy | 2 | 2013 | 221 | 0.600 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2017 | 134 | 0.600 |
Why?
|
| Carcinoma | 9 | 2021 | 448 | 0.590 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 22 | 0.590 |
Why?
|
| Cluster Analysis | 15 | 2014 | 393 | 0.590 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2010 | 209 | 0.590 |
Why?
|
| Odds Ratio | 23 | 2018 | 713 | 0.590 |
Why?
|
| Genetic Markers | 19 | 2013 | 479 | 0.580 |
Why?
|
| Myocardial Infarction | 9 | 2014 | 429 | 0.580 |
Why?
|
| Phosphoproteins | 5 | 2011 | 263 | 0.580 |
Why?
|
| Oxidoreductases, N-Demethylating | 3 | 2018 | 17 | 0.580 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2019 | 1471 | 0.580 |
Why?
|
| Cytochrome P-450 Enzyme System | 4 | 2016 | 78 | 0.570 |
Why?
|
| Reproducibility of Results | 23 | 2016 | 2880 | 0.570 |
Why?
|
| Immunogenetic Phenomena | 1 | 2018 | 5 | 0.570 |
Why?
|
| Collagen | 5 | 2011 | 306 | 0.570 |
Why?
|
| Chromosomes, Human, Pair 8 | 7 | 2013 | 83 | 0.560 |
Why?
|
| Antibodies, Monoclonal | 9 | 2018 | 1429 | 0.560 |
Why?
|
| Radioimmunotherapy | 6 | 2021 | 29 | 0.550 |
Why?
|
| Algorithms | 11 | 2019 | 2015 | 0.550 |
Why?
|
| Carcinoma, Small Cell | 5 | 2010 | 137 | 0.550 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 70 | 0.550 |
Why?
|
| Cadherins | 5 | 2016 | 179 | 0.550 |
Why?
|
| Calcium-Binding Proteins | 3 | 2016 | 120 | 0.550 |
Why?
|
| Interferons | 14 | 2012 | 130 | 0.550 |
Why?
|
| Genes, p53 | 9 | 2008 | 109 | 0.550 |
Why?
|
| E2F1 Transcription Factor | 5 | 2014 | 16 | 0.540 |
Why?
|
| Blood Proteins | 4 | 2012 | 151 | 0.540 |
Why?
|
| Fibronectins | 4 | 2016 | 100 | 0.540 |
Why?
|
| Peanut Hypersensitivity | 1 | 2017 | 17 | 0.540 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2016 | 169 | 0.540 |
Why?
|
| Chromosomes, Human, Pair 10 | 6 | 2013 | 47 | 0.530 |
Why?
|
| Glycosylation | 10 | 2019 | 137 | 0.530 |
Why?
|
| Chromosomes, Human, Pair 12 | 7 | 2021 | 65 | 0.530 |
Why?
|
| Pharmacogenomic Variants | 1 | 2017 | 44 | 0.530 |
Why?
|
| Neutropenia | 3 | 2013 | 218 | 0.530 |
Why?
|
| Lymphatic Metastasis | 13 | 2022 | 514 | 0.530 |
Why?
|
| Chromosomes, Human, Pair 14 | 3 | 2012 | 50 | 0.530 |
Why?
|
| Glucuronosyltransferase | 3 | 2012 | 186 | 0.530 |
Why?
|
| Neoplasm Invasiveness | 7 | 2024 | 580 | 0.530 |
Why?
|
| Young Adult | 36 | 2024 | 7025 | 0.530 |
Why?
|
| Postmenopause | 6 | 2017 | 107 | 0.520 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2010 | 115 | 0.520 |
Why?
|
| Hydrolases | 5 | 2012 | 30 | 0.520 |
Why?
|
| Homeodomain Proteins | 9 | 2018 | 563 | 0.520 |
Why?
|
| Amyotrophic Lateral Sclerosis | 6 | 2018 | 153 | 0.510 |
Why?
|
| Chromosomes, Human, Pair 13 | 10 | 2015 | 51 | 0.510 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 3 | 2012 | 22 | 0.510 |
Why?
|
| Nitriles | 5 | 2014 | 157 | 0.510 |
Why?
|
| Oncogene Proteins | 5 | 2018 | 65 | 0.510 |
Why?
|
| Enzyme Activation | 12 | 2016 | 692 | 0.500 |
Why?
|
| DNA Copy Number Variations | 6 | 2020 | 191 | 0.500 |
Why?
|
| HLA-B Antigens | 4 | 2020 | 28 | 0.500 |
Why?
|
| Triazoles | 5 | 2014 | 110 | 0.500 |
Why?
|
| Duodenal Ulcer | 2 | 2013 | 11 | 0.500 |
Why?
|
| Polymyositis | 1 | 2016 | 7 | 0.500 |
Why?
|
| Mannosyltransferases | 1 | 2016 | 7 | 0.500 |
Why?
|
| Hepatitis C | 8 | 2013 | 185 | 0.500 |
Why?
|
| Genetics, Population | 18 | 2013 | 437 | 0.490 |
Why?
|
| Cytokinesis | 2 | 2014 | 60 | 0.490 |
Why?
|
| Imidazoles | 2 | 2015 | 144 | 0.480 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 8 | 2010 | 190 | 0.480 |
Why?
|
| Pulmonary Veins | 1 | 2017 | 96 | 0.480 |
Why?
|
| DNA Mutational Analysis | 12 | 2018 | 547 | 0.480 |
Why?
|
| Phenotype | 22 | 2021 | 2578 | 0.480 |
Why?
|
| Interferon Type I | 5 | 2023 | 206 | 0.480 |
Why?
|
| Deoxycytidine | 7 | 2018 | 216 | 0.480 |
Why?
|
| Cell Growth Processes | 13 | 2012 | 83 | 0.470 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2012 | 713 | 0.470 |
Why?
|
| Disease Progression | 18 | 2016 | 1562 | 0.470 |
Why?
|
| Trachea | 1 | 2017 | 293 | 0.470 |
Why?
|
| Myasthenia Gravis | 1 | 2016 | 83 | 0.470 |
Why?
|
| Anticoagulants | 3 | 2013 | 463 | 0.470 |
Why?
|
| Gene Expression Regulation, Enzymologic | 7 | 2016 | 223 | 0.470 |
Why?
|
| Gene Dosage | 6 | 2014 | 212 | 0.470 |
Why?
|
| Anemia | 5 | 2023 | 137 | 0.460 |
Why?
|
| Acyltransferases | 2 | 2013 | 53 | 0.460 |
Why?
|
| RNA-Binding Proteins | 9 | 2018 | 305 | 0.460 |
Why?
|
| Osteosarcoma | 3 | 2024 | 160 | 0.460 |
Why?
|
| Mesothelioma | 2 | 2016 | 333 | 0.460 |
Why?
|
| Receptor, Endothelin A | 2 | 2012 | 21 | 0.450 |
Why?
|
| Cohort Studies | 26 | 2020 | 3110 | 0.450 |
Why?
|
| Unrelated Donors | 1 | 2015 | 47 | 0.450 |
Why?
|
| Nasopharyngeal Neoplasms | 5 | 2016 | 47 | 0.450 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2015 | 132 | 0.450 |
Why?
|
| Smoking | 8 | 2017 | 653 | 0.440 |
Why?
|
| Multidrug Resistance-Associated Proteins | 3 | 2011 | 25 | 0.440 |
Why?
|
| Pyrophosphatases | 6 | 2011 | 17 | 0.440 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2012 | 380 | 0.440 |
Why?
|
| L-Selectin | 3 | 2006 | 17 | 0.440 |
Why?
|
| Viral Core Proteins | 8 | 2012 | 28 | 0.440 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 6 | 2015 | 79 | 0.440 |
Why?
|
| Endometrial Neoplasms | 2 | 2017 | 228 | 0.440 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2014 | 6 | 0.440 |
Why?
|
| Aminopyridines | 1 | 2015 | 49 | 0.440 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2014 | 59 | 0.430 |
Why?
|
| Genetic Testing | 11 | 2021 | 565 | 0.430 |
Why?
|
| Helicobacter Infections | 2 | 2018 | 38 | 0.430 |
Why?
|
| Membrane Glycoproteins | 8 | 2012 | 453 | 0.430 |
Why?
|
| Exons | 16 | 2012 | 454 | 0.430 |
Why?
|
| Keloid | 2 | 2011 | 8 | 0.420 |
Why?
|
| Risk | 11 | 2014 | 668 | 0.420 |
Why?
|
| Anthracenes | 2 | 2013 | 13 | 0.420 |
Why?
|
| Graft vs Host Disease | 4 | 2020 | 368 | 0.420 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2014 | 33 | 0.420 |
Why?
|
| HIV Infections | 4 | 2011 | 974 | 0.420 |
Why?
|
| Adaptor Proteins, Signal Transducing | 8 | 2015 | 307 | 0.420 |
Why?
|
| Polyethylene Glycols | 8 | 2012 | 376 | 0.420 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2013 | 8 | 0.420 |
Why?
|
| Adenoma | 3 | 2013 | 260 | 0.420 |
Why?
|
| Gene Library | 4 | 2003 | 134 | 0.410 |
Why?
|
| Patient Selection | 2 | 2016 | 709 | 0.410 |
Why?
|
| Sulfonamides | 2 | 2013 | 337 | 0.410 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2020 | 126 | 0.410 |
Why?
|
| Leukocytes | 6 | 2014 | 218 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2012 | 109 | 0.400 |
Why?
|
| Thailand | 8 | 2012 | 66 | 0.400 |
Why?
|
| Helicobacter pylori | 1 | 2013 | 38 | 0.390 |
Why?
|
| Immunoenzyme Techniques | 13 | 2012 | 298 | 0.390 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2019 | 1973 | 0.390 |
Why?
|
| E-Selectin | 3 | 2006 | 31 | 0.390 |
Why?
|
| Phenanthrolines | 1 | 2013 | 8 | 0.390 |
Why?
|
| Coordination Complexes | 1 | 2013 | 20 | 0.390 |
Why?
|
| Zinc Fingers | 5 | 2013 | 60 | 0.390 |
Why?
|
| Edetic Acid | 1 | 2013 | 42 | 0.390 |
Why?
|
| Interleukin-2 | 2 | 2011 | 248 | 0.390 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2012 | 8 | 0.390 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 449 | 0.390 |
Why?
|
| Binding Sites | 19 | 2016 | 1167 | 0.390 |
Why?
|
| Tissue Distribution | 11 | 2023 | 297 | 0.390 |
Why?
|
| Alopecia | 1 | 2013 | 35 | 0.390 |
Why?
|
| Cytoplasm | 5 | 2017 | 288 | 0.390 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 113 | 0.390 |
Why?
|
| Aromatase Inhibitors | 5 | 2014 | 32 | 0.390 |
Why?
|
| Biomarkers | 10 | 2024 | 1930 | 0.390 |
Why?
|
| Chromosomes, Mammalian | 1 | 2013 | 38 | 0.380 |
Why?
|
| Tenascin | 3 | 2007 | 9 | 0.380 |
Why?
|
| Vestibule, Labyrinth | 2 | 2003 | 43 | 0.380 |
Why?
|
| Models, Genetic | 13 | 2016 | 984 | 0.380 |
Why?
|
| Platinum | 1 | 2013 | 67 | 0.380 |
Why?
|
| Sulfotransferases | 4 | 2016 | 19 | 0.380 |
Why?
|
| Doxorubicin | 8 | 2015 | 304 | 0.380 |
Why?
|
| Serum Albumin | 2 | 2012 | 128 | 0.380 |
Why?
|
| Mixed Function Oxygenases | 5 | 2013 | 69 | 0.380 |
Why?
|
| Germ-Line Mutation | 7 | 2021 | 382 | 0.380 |
Why?
|
| Protein Transport | 9 | 2017 | 439 | 0.380 |
Why?
|
| Antigen Presentation | 3 | 2025 | 229 | 0.380 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 3927 | 0.380 |
Why?
|
| Annexin A3 | 1 | 2012 | 1 | 0.370 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2012 | 1 | 0.370 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2012 | 8 | 0.370 |
Why?
|
| Paralysis, Hyperkalemic Periodic | 1 | 2012 | 1 | 0.370 |
Why?
|
| Zinc | 1 | 2013 | 101 | 0.370 |
Why?
|
| Antibodies | 3 | 2012 | 356 | 0.370 |
Why?
|
| Mammary Glands, Human | 2 | 2014 | 26 | 0.370 |
Why?
|
| Nuclear Envelope | 1 | 2012 | 39 | 0.370 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2020 | 173 | 0.370 |
Why?
|
| Forkhead Box Protein M1 | 6 | 2017 | 15 | 0.370 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 2 | 2011 | 5 | 0.370 |
Why?
|
| HLA-DR Antigens | 5 | 2009 | 59 | 0.370 |
Why?
|
| Camptothecin | 3 | 2009 | 204 | 0.370 |
Why?
|
| Genetics, Medical | 2 | 2010 | 51 | 0.370 |
Why?
|
| Gallbladder Neoplasms | 1 | 2012 | 23 | 0.360 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2012 | 19 | 0.360 |
Why?
|
| Paclitaxel | 5 | 2015 | 497 | 0.360 |
Why?
|
| Endometriosis | 3 | 2012 | 63 | 0.360 |
Why?
|
| Brain Neoplasms | 3 | 2009 | 854 | 0.360 |
Why?
|
| Tissue Extracts | 1 | 2011 | 25 | 0.360 |
Why?
|
| Thyroid Neoplasms | 3 | 2015 | 443 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 22 | 5 | 2011 | 41 | 0.360 |
Why?
|
| Benzoxazines | 1 | 2011 | 6 | 0.360 |
Why?
|
| Liver | 10 | 2016 | 1238 | 0.360 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2011 | 23 | 0.360 |
Why?
|
| Hyperthyroidism | 1 | 2012 | 76 | 0.360 |
Why?
|
| Tissue Array Analysis | 13 | 2016 | 132 | 0.360 |
Why?
|
| Leukocyte Count | 6 | 2016 | 228 | 0.360 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2015 | 379 | 0.350 |
Why?
|
| Models, Biological | 10 | 2017 | 1809 | 0.350 |
Why?
|
| Antibiotics, Antineoplastic | 6 | 2015 | 114 | 0.350 |
Why?
|
| Recombinant Proteins | 17 | 2014 | 1034 | 0.350 |
Why?
|
| Dermatitis, Atopic | 4 | 2013 | 66 | 0.350 |
Why?
|
| Epithelial Cells | 8 | 2017 | 705 | 0.350 |
Why?
|
| Patient Care | 1 | 2012 | 101 | 0.350 |
Why?
|
| Melanoma | 1 | 2016 | 497 | 0.350 |
Why?
|
| Schizophrenia | 2 | 2013 | 532 | 0.350 |
Why?
|
| Prostatic Hyperplasia | 1 | 2012 | 97 | 0.350 |
Why?
|
| Prospective Studies | 10 | 2022 | 4671 | 0.350 |
Why?
|
| Vitamin K Epoxide Reductases | 5 | 2019 | 16 | 0.340 |
Why?
|
| Drug Eruptions | 1 | 2011 | 35 | 0.340 |
Why?
|
| Cytochrome P-450 CYP2C9 | 5 | 2019 | 20 | 0.340 |
Why?
|
| Lim Kinases | 1 | 2011 | 3 | 0.340 |
Why?
|
| HLA-DP Antigens | 4 | 2011 | 9 | 0.340 |
Why?
|
| Mitochondrial Proteins | 4 | 2010 | 129 | 0.340 |
Why?
|
| beta Catenin | 10 | 2011 | 266 | 0.340 |
Why?
|
| Logistic Models | 11 | 2013 | 1268 | 0.340 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 3 | 2023 | 38 | 0.340 |
Why?
|
| Mice, Inbred BALB C | 18 | 2018 | 1124 | 0.340 |
Why?
|
| Cell Survival | 16 | 2017 | 1030 | 0.340 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2011 | 16 | 0.340 |
Why?
|
| Organic Anion Transporters | 2 | 2008 | 26 | 0.340 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 48 | 0.340 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2015 | 276 | 0.340 |
Why?
|
| Membrane Transport Proteins | 4 | 2012 | 170 | 0.340 |
Why?
|
| Carbamazepine | 1 | 2010 | 10 | 0.340 |
Why?
|
| Adolescent | 31 | 2024 | 9895 | 0.340 |
Why?
|
| Child | 25 | 2024 | 7625 | 0.330 |
Why?
|
| Computational Biology | 10 | 2017 | 586 | 0.330 |
Why?
|
| Nerve Tissue Proteins | 6 | 2012 | 515 | 0.330 |
Why?
|
| Sirtuin 1 | 1 | 2011 | 37 | 0.330 |
Why?
|
| Body Mass Index | 6 | 2012 | 815 | 0.330 |
Why?
|
| RNA, Antisense | 1 | 2010 | 15 | 0.330 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 625 | 0.330 |
Why?
|
| Polyglutamic Acid | 1 | 2010 | 15 | 0.330 |
Why?
|
| Peptide Synthases | 1 | 2010 | 12 | 0.330 |
Why?
|
| Multigene Family | 7 | 2014 | 213 | 0.320 |
Why?
|
| Mice, Nude | 14 | 2018 | 830 | 0.320 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2010 | 24 | 0.320 |
Why?
|
| Aspirin | 4 | 2017 | 169 | 0.320 |
Why?
|
| Cyclophosphamide | 3 | 2018 | 313 | 0.320 |
Why?
|
| Epigenesis, Genetic | 5 | 2018 | 555 | 0.310 |
Why?
|
| MCF-7 Cells | 6 | 2016 | 120 | 0.310 |
Why?
|
| Organ Specificity | 9 | 2014 | 286 | 0.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 395 | 0.310 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2010 | 82 | 0.310 |
Why?
|
| Lectins, C-Type | 5 | 2011 | 89 | 0.310 |
Why?
|
| Proteinuria | 1 | 2010 | 69 | 0.310 |
Why?
|
| Gamma Rays | 5 | 2014 | 73 | 0.310 |
Why?
|
| Anticonvulsants | 1 | 2010 | 133 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2012 | 107 | 0.310 |
Why?
|
| Aldehyde Dehydrogenase | 3 | 2009 | 17 | 0.310 |
Why?
|
| Plagiarism | 1 | 2009 | 8 | 0.310 |
Why?
|
| Scientific Misconduct | 1 | 2009 | 10 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2017 | 595 | 0.310 |
Why?
|
| Morphogenesis | 1 | 2011 | 211 | 0.310 |
Why?
|
| Alcohol Dehydrogenase | 3 | 2009 | 42 | 0.310 |
Why?
|
| Uterine Neoplasms | 1 | 2013 | 278 | 0.300 |
Why?
|
| Predictive Value of Tests | 10 | 2011 | 1805 | 0.300 |
Why?
|
| Receptors, Drug | 3 | 2005 | 54 | 0.300 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2009 | 4 | 0.300 |
Why?
|
| Receptors, Serotonin | 1 | 2009 | 34 | 0.300 |
Why?
|
| Papillomavirus Infections | 4 | 2023 | 301 | 0.300 |
Why?
|
| Retinoblastoma Protein | 4 | 2015 | 68 | 0.300 |
Why?
|
| Principal Component Analysis | 5 | 2014 | 168 | 0.300 |
Why?
|
| Chlamydophila Infections | 1 | 2009 | 3 | 0.300 |
Why?
|
| Gene Silencing | 10 | 2016 | 181 | 0.300 |
Why?
|
| Receptor, ErbB-2 | 5 | 2020 | 280 | 0.300 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2009 | 13 | 0.300 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2006 | 50 | 0.300 |
Why?
|
| Flow Cytometry | 15 | 2014 | 728 | 0.300 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2009 | 29 | 0.300 |
Why?
|
| Cells, Cultured | 18 | 2018 | 2939 | 0.290 |
Why?
|
| Loss of Heterozygosity | 4 | 2014 | 86 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 3 | 8 | 2012 | 54 | 0.290 |
Why?
|
| Antigens, CD | 3 | 2019 | 481 | 0.290 |
Why?
|
| Testicular Neoplasms | 3 | 2005 | 123 | 0.290 |
Why?
|
| Time Factors | 16 | 2016 | 5580 | 0.290 |
Why?
|
| Structure-Activity Relationship | 5 | 2015 | 436 | 0.290 |
Why?
|
| Major Histocompatibility Complex | 5 | 2021 | 86 | 0.290 |
Why?
|
| Kidney | 10 | 2016 | 1137 | 0.290 |
Why?
|
| Artificial Intelligence | 3 | 2024 | 398 | 0.290 |
Why?
|
| Proliferating Cell Nuclear Antigen | 3 | 2017 | 68 | 0.280 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2015 | 91 | 0.280 |
Why?
|
| Exanthema | 1 | 2009 | 41 | 0.280 |
Why?
|
| Child, Preschool | 16 | 2017 | 3974 | 0.280 |
Why?
|
| Bone Neoplasms | 3 | 2024 | 319 | 0.280 |
Why?
|
| Histone Demethylases | 3 | 2015 | 34 | 0.280 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2020 | 149 | 0.280 |
Why?
|
| Drug Screening Assays, Antitumor | 6 | 2016 | 84 | 0.280 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2008 | 5 | 0.280 |
Why?
|
| Bone Marrow Cells | 3 | 2016 | 279 | 0.280 |
Why?
|
| Mass Spectrometry | 9 | 2015 | 206 | 0.280 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2015 | 157 | 0.280 |
Why?
|
| Cisplatin | 8 | 2014 | 611 | 0.280 |
Why?
|
| HLA-DRB1 Chains | 7 | 2013 | 24 | 0.280 |
Why?
|
| Anticarcinogenic Agents | 2 | 2013 | 71 | 0.280 |
Why?
|
| Proteasome Endopeptidase Complex | 5 | 2013 | 112 | 0.280 |
Why?
|
| Muscular Diseases | 1 | 2008 | 68 | 0.280 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2015 | 284 | 0.270 |
Why?
|
| Cation Transport Proteins | 3 | 2007 | 70 | 0.270 |
Why?
|
| Simvastatin | 1 | 2008 | 106 | 0.270 |
Why?
|
| Adenosine Triphosphatases | 4 | 2024 | 156 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2022 | 17 | 0.270 |
Why?
|
| Carbon-Carbon Ligases | 1 | 2007 | 2 | 0.270 |
Why?
|
| HCT116 Cells | 9 | 2016 | 164 | 0.270 |
Why?
|
| Piperazines | 3 | 2007 | 296 | 0.270 |
Why?
|
| Protein-Arginine Deiminases | 6 | 2018 | 6 | 0.270 |
Why?
|
| Peritoneal Neoplasms | 2 | 2020 | 187 | 0.270 |
Why?
|
| Cell Membrane Permeability | 4 | 2018 | 121 | 0.270 |
Why?
|
| Metabolic Syndrome | 1 | 2009 | 123 | 0.270 |
Why?
|
| Retrospective Studies | 13 | 2025 | 10287 | 0.270 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2003 | 176 | 0.270 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 258 | 0.270 |
Why?
|
| Pyrimidines | 4 | 2007 | 386 | 0.270 |
Why?
|
| Metalloendopeptidases | 2 | 2004 | 44 | 0.270 |
Why?
|
| Abnormalities, Multiple | 1 | 2009 | 238 | 0.270 |
Why?
|
| Toxicogenetics | 1 | 2007 | 1 | 0.270 |
Why?
|
| Survival Rate | 7 | 2020 | 1985 | 0.270 |
Why?
|
| Immune Tolerance | 2 | 2009 | 385 | 0.260 |
Why?
|
| Drug Discovery | 2 | 2021 | 118 | 0.260 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2018 | 301 | 0.260 |
Why?
|
| Seminoma | 2 | 2004 | 15 | 0.260 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2007 | 38 | 0.260 |
Why?
|
| Blood Coagulation | 1 | 2007 | 90 | 0.260 |
Why?
|
| RNA | 7 | 2016 | 605 | 0.260 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2017 | 159 | 0.260 |
Why?
|
| Leiomyoma | 1 | 2011 | 211 | 0.260 |
Why?
|
| Neuroblastoma | 2 | 2019 | 400 | 0.260 |
Why?
|
| Protein Isoforms | 7 | 2011 | 296 | 0.260 |
Why?
|
| Betacoronavirus | 2 | 2020 | 284 | 0.260 |
Why?
|
| Survival Analysis | 11 | 2020 | 1546 | 0.260 |
Why?
|
| Opisthorchiasis | 1 | 2006 | 1 | 0.250 |
Why?
|
| Oligopeptides | 4 | 2012 | 193 | 0.250 |
Why?
|
| Chromatin | 6 | 2014 | 450 | 0.250 |
Why?
|
| Oxidoreductases | 2 | 2015 | 115 | 0.250 |
Why?
|
| Apoptosis Regulatory Proteins | 7 | 2012 | 204 | 0.250 |
Why?
|
| Tandem Repeat Sequences | 2 | 2009 | 31 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 247 | 0.250 |
Why?
|
| Hepatitis B, Chronic | 3 | 2012 | 34 | 0.250 |
Why?
|
| Fibroblast Growth Factors | 2 | 2005 | 86 | 0.250 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2021 | 34 | 0.250 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2009 | 88 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 4 | 5 | 2012 | 47 | 0.250 |
Why?
|
| Radiation Tolerance | 2 | 2009 | 176 | 0.250 |
Why?
|
| Brain Ischemia | 3 | 2010 | 416 | 0.250 |
Why?
|
| Carcinogenesis | 5 | 2020 | 235 | 0.250 |
Why?
|
| Cytokines | 7 | 2018 | 871 | 0.250 |
Why?
|
| HLA-A2 Antigen | 6 | 2014 | 32 | 0.240 |
Why?
|
| Estrogens | 3 | 2020 | 203 | 0.240 |
Why?
|
| Cyclins | 2 | 2003 | 80 | 0.240 |
Why?
|
| Mice, SCID | 6 | 2016 | 279 | 0.240 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 405 | 0.240 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2025 | 94 | 0.240 |
Why?
|
| Homozygote | 7 | 2012 | 208 | 0.240 |
Why?
|
| Genetic Linkage | 9 | 2010 | 623 | 0.240 |
Why?
|
| Immunoglobulins | 2 | 2012 | 144 | 0.240 |
Why?
|
| Neoplasm Metastasis | 8 | 2020 | 1094 | 0.240 |
Why?
|
| Genes, Reporter | 6 | 2014 | 281 | 0.240 |
Why?
|
| Mice, Knockout | 12 | 2020 | 2161 | 0.240 |
Why?
|
| Genome | 4 | 2004 | 407 | 0.240 |
Why?
|
| Disease | 2 | 2017 | 93 | 0.240 |
Why?
|
| Mitochondria | 6 | 2008 | 622 | 0.240 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2025 | 42 | 0.240 |
Why?
|
| Cochlea | 2 | 2003 | 50 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 7 | 4 | 2013 | 81 | 0.240 |
Why?
|
| Coculture Techniques | 3 | 2022 | 172 | 0.240 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 901 | 0.240 |
Why?
|
| Stroke | 3 | 2010 | 1087 | 0.240 |
Why?
|
| Models, Statistical | 6 | 2016 | 594 | 0.240 |
Why?
|
| Cytochrome P450 Family 4 | 2 | 2019 | 3 | 0.230 |
Why?
|
| Contractile Proteins | 1 | 2005 | 57 | 0.230 |
Why?
|
| Cell Differentiation | 8 | 2018 | 1667 | 0.230 |
Why?
|
| Sensitivity and Specificity | 9 | 2024 | 2039 | 0.230 |
Why?
|
| Genes, MHC Class II | 2 | 2003 | 31 | 0.230 |
Why?
|
| Obesity, Morbid | 1 | 2008 | 247 | 0.230 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2017 | 91 | 0.230 |
Why?
|
| Frameshift Mutation | 1 | 2025 | 54 | 0.230 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2017 | 111 | 0.230 |
Why?
|
| Protein Structure, Tertiary | 11 | 2012 | 750 | 0.230 |
Why?
|
| Cloning, Molecular | 8 | 2012 | 648 | 0.230 |
Why?
|
| Osteoarthritis, Knee | 4 | 2010 | 71 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 334 | 0.220 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2005 | 57 | 0.220 |
Why?
|
| Galectin 1 | 1 | 2004 | 6 | 0.220 |
Why?
|
| KCNQ1 Potassium Channel | 3 | 2010 | 17 | 0.220 |
Why?
|
| Intestinal Neoplasms | 2 | 2008 | 70 | 0.220 |
Why?
|
| Cholesterol | 2 | 2017 | 369 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2025 | 37 | 0.220 |
Why?
|
| Sequence Homology, Amino Acid | 6 | 2005 | 422 | 0.220 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2010 | 16 | 0.220 |
Why?
|
| Dinucleoside Phosphates | 1 | 2004 | 10 | 0.220 |
Why?
|
| Point Mutation | 2 | 2015 | 247 | 0.220 |
Why?
|
| Meta-Analysis as Topic | 6 | 2021 | 84 | 0.220 |
Why?
|
| RNA Splice Sites | 3 | 2012 | 58 | 0.220 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2004 | 19 | 0.220 |
Why?
|
| Bile Ducts, Intrahepatic | 5 | 2010 | 68 | 0.220 |
Why?
|
| B-Lymphocytes | 5 | 2024 | 771 | 0.220 |
Why?
|
| Neuropeptides | 3 | 2013 | 116 | 0.220 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 59 | 0.220 |
Why?
|
| Receptors, Calcitriol | 2 | 2018 | 131 | 0.220 |
Why?
|
| GTP-Binding Protein alpha Subunits, G12-G13 | 1 | 2004 | 6 | 0.220 |
Why?
|
| Protein Multimerization | 2 | 2017 | 196 | 0.220 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 1979 | 0.220 |
Why?
|
| Pharmacokinetics | 1 | 2004 | 11 | 0.220 |
Why?
|
| MutL Protein Homolog 1 | 3 | 2021 | 36 | 0.220 |
Why?
|
| Chromosome Banding | 1 | 2004 | 73 | 0.210 |
Why?
|
| Drug Administration Schedule | 5 | 2016 | 873 | 0.210 |
Why?
|
| Exosomes | 1 | 2025 | 60 | 0.210 |
Why?
|
| Colitis, Ulcerative | 4 | 2013 | 801 | 0.210 |
Why?
|
| Lung | 9 | 2018 | 1384 | 0.210 |
Why?
|
| Bronchodilator Agents | 3 | 2013 | 70 | 0.210 |
Why?
|
| Electrophoretic Mobility Shift Assay | 12 | 2013 | 75 | 0.210 |
Why?
|
| Depressive Disorder, Major | 2 | 2018 | 174 | 0.210 |
Why?
|
| Tumor Burden | 3 | 2021 | 322 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 12 | 2024 | 3489 | 0.210 |
Why?
|
| Yttrium Radioisotopes | 3 | 2021 | 48 | 0.210 |
Why?
|
| Medical Oncology | 1 | 2008 | 408 | 0.210 |
Why?
|
| Multiple Myeloma | 2 | 2019 | 354 | 0.210 |
Why?
|
| Bone Development | 1 | 2004 | 38 | 0.210 |
Why?
|
| Extracellular Matrix Proteins | 5 | 2009 | 130 | 0.210 |
Why?
|
| Histone Deacetylases | 1 | 2004 | 86 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2017 | 105 | 0.210 |
Why?
|
| Monocytes | 1 | 2025 | 231 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 249 | 0.210 |
Why?
|
| BRCA1 Protein | 2 | 2017 | 216 | 0.210 |
Why?
|
| Cartilage, Articular | 2 | 2010 | 78 | 0.210 |
Why?
|
| Receptors, Steroid | 2 | 2016 | 43 | 0.200 |
Why?
|
| Kruppel-Like Transcription Factors | 3 | 2012 | 109 | 0.200 |
Why?
|
| Cartilage | 2 | 2003 | 116 | 0.200 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 46 | 0.200 |
Why?
|
| Rats | 8 | 2015 | 4155 | 0.200 |
Why?
|
| Risk Assessment | 7 | 2017 | 2480 | 0.200 |
Why?
|
| Receptors, Polymeric Immunoglobulin | 1 | 2003 | 5 | 0.200 |
Why?
|
| Hematinics | 1 | 2023 | 11 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2016 | 81 | 0.200 |
Why?
|
| Chelating Agents | 1 | 2023 | 68 | 0.200 |
Why?
|
| Esterases | 1 | 2003 | 13 | 0.200 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2020 | 8 | 0.200 |
Why?
|
| Ligases | 1 | 2003 | 47 | 0.200 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2018 | 244 | 0.200 |
Why?
|
| DNA Replication | 5 | 2017 | 177 | 0.200 |
Why?
|
| Ovarian Cysts | 1 | 2003 | 17 | 0.200 |
Why?
|
| Embryonic Stem Cells | 2 | 2018 | 87 | 0.200 |
Why?
|
| Transglutaminases | 1 | 2003 | 41 | 0.200 |
Why?
|
| Ovarian Diseases | 1 | 2003 | 32 | 0.200 |
Why?
|
| Receptors, Immunologic | 3 | 2009 | 145 | 0.200 |
Why?
|
| CpG Islands | 1 | 2003 | 169 | 0.200 |
Why?
|
| Disease Susceptibility | 7 | 2010 | 220 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 1021 | 0.200 |
Why?
|
| Hearing Loss | 1 | 2003 | 65 | 0.200 |
Why?
|
| Crystallins | 1 | 2002 | 5 | 0.200 |
Why?
|
| Proteomics | 5 | 2018 | 268 | 0.190 |
Why?
|
| Remission Induction | 4 | 2021 | 769 | 0.190 |
Why?
|
| Bulgaria | 3 | 2013 | 3 | 0.190 |
Why?
|
| Substrate Specificity | 3 | 2018 | 368 | 0.190 |
Why?
|
| Mitosis | 2 | 2015 | 159 | 0.190 |
Why?
|
| Deafness | 1 | 2002 | 48 | 0.190 |
Why?
|
| Erythropoietin | 1 | 2023 | 91 | 0.190 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2003 | 43 | 0.190 |
Why?
|
| Mice, Inbred NOD | 5 | 2016 | 215 | 0.190 |
Why?
|
| RNA-Binding Protein EWS | 4 | 2018 | 8 | 0.190 |
Why?
|
| Cell Death | 3 | 2014 | 264 | 0.190 |
Why?
|
| Oxonic Acid | 4 | 2012 | 8 | 0.190 |
Why?
|
| Lymphocyte Activation | 6 | 2025 | 810 | 0.190 |
Why?
|
| Tegafur | 4 | 2012 | 17 | 0.190 |
Why?
|
| Gene Deletion | 4 | 2007 | 358 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 15 | 5 | 2014 | 66 | 0.190 |
Why?
|
| Administration, Oral | 4 | 2015 | 688 | 0.190 |
Why?
|
| Oligonucleotides, Antisense | 6 | 2005 | 67 | 0.190 |
Why?
|
| Isoenzymes | 3 | 2013 | 278 | 0.190 |
Why?
|
| Nephrolithiasis | 2 | 2013 | 25 | 0.190 |
Why?
|
| Sulindac | 1 | 2002 | 8 | 0.190 |
Why?
|
| Estradiol | 3 | 2013 | 255 | 0.190 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2024 | 290 | 0.190 |
Why?
|
| Polysaccharides | 3 | 2012 | 96 | 0.190 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 257 | 0.190 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2012 | 50 | 0.190 |
Why?
|
| Multiple Sclerosis | 1 | 2024 | 263 | 0.180 |
Why?
|
| Arginine | 4 | 2015 | 144 | 0.180 |
Why?
|
| Actinium | 1 | 2021 | 1 | 0.180 |
Why?
|
| Homeostasis | 2 | 2015 | 467 | 0.180 |
Why?
|
| ROC Curve | 7 | 2014 | 797 | 0.180 |
Why?
|
| Granuloma | 2 | 2019 | 65 | 0.180 |
Why?
|
| Drug Combinations | 5 | 2012 | 214 | 0.180 |
Why?
|
| Luciferases | 9 | 2013 | 130 | 0.180 |
Why?
|
| Cytodiagnosis | 2 | 2019 | 47 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 59 | 0.180 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 3 | 2013 | 8 | 0.180 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 40 | 0.180 |
Why?
|
| Drug Therapy, Combination | 9 | 2018 | 813 | 0.180 |
Why?
|
| Knee Joint | 1 | 2003 | 166 | 0.180 |
Why?
|
| Oncogenes | 3 | 2007 | 100 | 0.180 |
Why?
|
| Actins | 2 | 2020 | 473 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 138 | 0.180 |
Why?
|
| BCG Vaccine | 2 | 2020 | 38 | 0.180 |
Why?
|
| Transcription Factor TFIIIA | 2 | 2012 | 2 | 0.180 |
Why?
|
| Microfilament Proteins | 6 | 2013 | 213 | 0.180 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 2002 | 36 | 0.180 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 19 | 0.180 |
Why?
|
| Lymphocytes | 2 | 2022 | 489 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 7 | 2018 | 299 | 0.180 |
Why?
|
| beta-Defensins | 2 | 2018 | 12 | 0.180 |
Why?
|
| Chromosomal Instability | 2 | 2014 | 23 | 0.170 |
Why?
|
| Osteoporosis | 2 | 2014 | 131 | 0.170 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 6 | 2014 | 82 | 0.170 |
Why?
|
| Mesoderm | 1 | 2002 | 122 | 0.170 |
Why?
|
| MAP Kinase Signaling System | 5 | 2015 | 206 | 0.170 |
Why?
|
| Fungal Proteins | 1 | 2002 | 147 | 0.170 |
Why?
|
| Fucose | 2 | 2012 | 14 | 0.170 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2003 | 308 | 0.170 |
Why?
|
| Calcium Channels | 2 | 2013 | 183 | 0.170 |
Why?
|
| TCF Transcription Factors | 4 | 2005 | 26 | 0.170 |
Why?
|
| RNA, Neoplasm | 4 | 2016 | 89 | 0.170 |
Why?
|
| 3T3 Cells | 4 | 2005 | 98 | 0.170 |
Why?
|
| Stavudine | 2 | 2011 | 4 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-ets | 3 | 2013 | 27 | 0.170 |
Why?
|
| Dyslipidemias | 2 | 2017 | 109 | 0.170 |
Why?
|
| Histocompatibility Antigens | 2 | 2011 | 37 | 0.170 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 30 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2012 | 107 | 0.170 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 404 | 0.170 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 2 | 2012 | 10 | 0.170 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 33 | 0.170 |
Why?
|
| Models, Molecular | 3 | 2015 | 1375 | 0.170 |
Why?
|
| Osteoarthritis | 3 | 2007 | 85 | 0.170 |
Why?
|
| Chromatin Immunoprecipitation | 8 | 2016 | 142 | 0.170 |
Why?
|
| Enzyme Inhibitors | 4 | 2018 | 656 | 0.170 |
Why?
|
| Rectal Neoplasms | 3 | 2019 | 134 | 0.170 |
Why?
|
| CA-125 Antigen | 1 | 2020 | 21 | 0.160 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 191 | 0.160 |
Why?
|
| Cellular Senescence | 3 | 2012 | 106 | 0.160 |
Why?
|
| Vaginal Neoplasms | 1 | 2020 | 84 | 0.160 |
Why?
|
| DNA Fragmentation | 1 | 2020 | 65 | 0.160 |
Why?
|
| Herpesvirus 1, Human | 2 | 2018 | 245 | 0.160 |
Why?
|
| Mucin-1 | 2 | 2010 | 46 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2017 | 564 | 0.160 |
Why?
|
| Carcinogens | 1 | 2020 | 106 | 0.160 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2016 | 423 | 0.160 |
Why?
|
| Biological Assay | 2 | 2010 | 84 | 0.160 |
Why?
|
| CD8 Antigens | 2 | 2017 | 84 | 0.160 |
Why?
|
| Biosensing Techniques | 2 | 2020 | 81 | 0.160 |
Why?
|
| Blood | 1 | 2020 | 69 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 5 | 2 | 2012 | 13 | 0.160 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 2 | 2010 | 31 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 6 | 2011 | 349 | 0.160 |
Why?
|
| Breast | 2 | 2019 | 297 | 0.160 |
Why?
|
| Granzymes | 2 | 2017 | 96 | 0.160 |
Why?
|
| GPI-Linked Proteins | 8 | 2013 | 55 | 0.160 |
Why?
|
| 3' Untranslated Regions | 6 | 2009 | 100 | 0.160 |
Why?
|
| Myofibroblasts | 1 | 2020 | 51 | 0.160 |
Why?
|
| Viral Vaccines | 1 | 2020 | 48 | 0.160 |
Why?
|
| Coronavirus | 1 | 2020 | 20 | 0.160 |
Why?
|
| Autocrine Communication | 1 | 2019 | 21 | 0.160 |
Why?
|
| 5' Untranslated Regions | 4 | 2012 | 54 | 0.160 |
Why?
|
| Open Reading Frames | 1 | 2020 | 124 | 0.160 |
Why?
|
| Th1 Cells | 2 | 2018 | 171 | 0.160 |
Why?
|
| Aging | 2 | 2016 | 766 | 0.160 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 2 | 2014 | 5 | 0.160 |
Why?
|
| Urinary Bladder | 3 | 2018 | 263 | 0.160 |
Why?
|
| NF-kappa B | 6 | 2012 | 469 | 0.160 |
Why?
|
| Bone and Bones | 2 | 2013 | 280 | 0.160 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 76 | 0.160 |
Why?
|
| Antigens, Ly | 3 | 2008 | 37 | 0.160 |
Why?
|
| Molecular Structure | 3 | 2015 | 310 | 0.150 |
Why?
|
| Peptides, Cyclic | 2 | 2009 | 44 | 0.150 |
Why?
|
| Protein Kinase C | 2 | 2013 | 267 | 0.150 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2017 | 90 | 0.150 |
Why?
|
| Protons | 1 | 2020 | 104 | 0.150 |
Why?
|
| Datasets as Topic | 1 | 2019 | 82 | 0.150 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 2 | 2011 | 20 | 0.150 |
Why?
|
| Cathepsins | 2 | 2013 | 22 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 3 | 2015 | 89 | 0.150 |
Why?
|
| 5' Flanking Region | 5 | 2007 | 16 | 0.150 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 179 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 180 | 0.150 |
Why?
|
| Lung Abscess | 1 | 2019 | 5 | 0.150 |
Why?
|
| Sodium | 2 | 2011 | 340 | 0.150 |
Why?
|
| Genetic Vectors | 7 | 2016 | 446 | 0.150 |
Why?
|
| HSP70 Heat-Shock Proteins | 3 | 2012 | 118 | 0.150 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2017 | 78 | 0.150 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 61 | 0.150 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2012 | 124 | 0.150 |
Why?
|
| Protein Interaction Mapping | 3 | 2011 | 81 | 0.150 |
Why?
|
| Coumarins | 1 | 2019 | 14 | 0.150 |
Why?
|
| Osteoarthritis, Hip | 3 | 2010 | 22 | 0.150 |
Why?
|
| Stem Cells | 1 | 2002 | 394 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 166 | 0.150 |
Why?
|
| Serpins | 2 | 2012 | 31 | 0.150 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2015 | 34 | 0.150 |
Why?
|
| Population Groups | 4 | 2012 | 42 | 0.150 |
Why?
|
| Hemoglobins | 3 | 2023 | 196 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 225 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2018 | 32 | 0.150 |
Why?
|
| Brain | 4 | 2020 | 2482 | 0.150 |
Why?
|
| Sesquiterpenes | 1 | 2018 | 13 | 0.140 |
Why?
|
| Cytotoxins | 1 | 2018 | 17 | 0.140 |
Why?
|
| Astatine | 1 | 2018 | 3 | 0.140 |
Why?
|
| Combined Modality Therapy | 9 | 2018 | 1773 | 0.140 |
Why?
|
| Raloxifene Hydrochloride | 3 | 2015 | 10 | 0.140 |
Why?
|
| Genetic Techniques | 2 | 2009 | 75 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 4 | 2016 | 180 | 0.140 |
Why?
|
| RNA, Untranslated | 2 | 2010 | 69 | 0.140 |
Why?
|
| Regression Analysis | 3 | 2013 | 599 | 0.140 |
Why?
|
| Radioisotopes | 1 | 2018 | 43 | 0.140 |
Why?
|
| Sialoglycoproteins | 2 | 2010 | 31 | 0.140 |
Why?
|
| Receptors, IgG | 3 | 2013 | 68 | 0.140 |
Why?
|
| Software | 5 | 2011 | 698 | 0.140 |
Why?
|
| Autoantigens | 5 | 2013 | 139 | 0.140 |
Why?
|
| Microsomes, Liver | 2 | 2015 | 49 | 0.140 |
Why?
|
| Macrophages | 2 | 2020 | 623 | 0.140 |
Why?
|
| Oncolytic Viruses | 1 | 2018 | 24 | 0.140 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 60 | 0.140 |
Why?
|
| Hepatitis B virus | 3 | 2012 | 48 | 0.140 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 263 | 0.140 |
Why?
|
| Europe | 4 | 2013 | 349 | 0.140 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 165 | 0.140 |
Why?
|
| eIF-2 Kinase | 2 | 2015 | 50 | 0.140 |
Why?
|
| Receptors, Progesterone | 4 | 2020 | 196 | 0.140 |
Why?
|
| Lymph Node Excision | 3 | 2014 | 235 | 0.140 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 381 | 0.140 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2018 | 26 | 0.140 |
Why?
|
| Kynurenine | 1 | 2018 | 23 | 0.140 |
Why?
|
| Cyanobacteria | 1 | 2018 | 114 | 0.130 |
Why?
|
| Acetylation | 3 | 2015 | 149 | 0.130 |
Why?
|
| Cardiovascular Diseases | 3 | 2017 | 777 | 0.130 |
Why?
|
| Uric Acid | 3 | 2012 | 137 | 0.130 |
Why?
|
| Mediastinal Cyst | 1 | 2017 | 3 | 0.130 |
Why?
|
| Bronchogenic Cyst | 1 | 2017 | 5 | 0.130 |
Why?
|
| Calmodulin | 2 | 2010 | 51 | 0.130 |
Why?
|
| Interferon-gamma | 7 | 2018 | 467 | 0.130 |
Why?
|
| Nod2 Signaling Adaptor Protein | 2 | 2011 | 14 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2015 | 68 | 0.130 |
Why?
|
| Papillomaviridae | 2 | 2017 | 180 | 0.130 |
Why?
|
| Fever | 1 | 2018 | 131 | 0.130 |
Why?
|
| Estrone | 1 | 2017 | 10 | 0.130 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2010 | 282 | 0.130 |
Why?
|
| Citalopram | 2 | 2014 | 21 | 0.130 |
Why?
|
| Artifacts | 2 | 2016 | 252 | 0.130 |
Why?
|
| Gene Transfer Techniques | 3 | 2008 | 156 | 0.130 |
Why?
|
| Early Growth Response Protein 2 | 2 | 2010 | 17 | 0.130 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2017 | 23 | 0.130 |
Why?
|
| Thy-1 Antigens | 1 | 2017 | 16 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 151 | 0.130 |
Why?
|
| United Kingdom | 3 | 2010 | 192 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2777 | 0.130 |
Why?
|
| Lasers | 4 | 2005 | 102 | 0.130 |
Why?
|
| CD11c Antigen | 1 | 2017 | 20 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 2 | 3 | 2012 | 85 | 0.130 |
Why?
|
| Telomere Homeostasis | 1 | 2017 | 30 | 0.130 |
Why?
|
| Lectins | 3 | 2012 | 86 | 0.130 |
Why?
|
| Ubiquitination | 3 | 2015 | 81 | 0.130 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2017 | 34 | 0.130 |
Why?
|
| Chloride Channels | 2 | 2019 | 43 | 0.130 |
Why?
|
| Pleckstrin Homology Domains | 1 | 2016 | 1 | 0.130 |
Why?
|
| Diabetic Neuropathies | 2 | 2007 | 41 | 0.130 |
Why?
|
| Thrombosis | 2 | 2010 | 326 | 0.130 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 31 | 0.130 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 50 | 0.130 |
Why?
|
| Butyrylcholinesterase | 1 | 2016 | 12 | 0.130 |
Why?
|
| Caspases | 4 | 2005 | 156 | 0.130 |
Why?
|
| Expressed Sequence Tags | 4 | 2004 | 35 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 47 | 0.130 |
Why?
|
| RNA Helicases | 2 | 2009 | 36 | 0.130 |
Why?
|
| Serine | 4 | 2011 | 108 | 0.130 |
Why?
|
| Endoscopy | 1 | 2020 | 374 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2011 | 178 | 0.130 |
Why?
|
| Epilepsy | 1 | 2021 | 451 | 0.130 |
Why?
|
| Ki-67 Antigen | 1 | 2016 | 67 | 0.130 |
Why?
|
| Kinetics | 3 | 2005 | 1562 | 0.130 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 91 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 3 | 2017 | 346 | 0.120 |
Why?
|
| Interleukin-17 | 3 | 2012 | 110 | 0.120 |
Why?
|
| Dyneins | 1 | 2016 | 14 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2016 | 25 | 0.120 |
Why?
|
| Cystatins | 2 | 2008 | 5 | 0.120 |
Why?
|
| Azacitidine | 2 | 2014 | 150 | 0.120 |
Why?
|
| Histocompatibility Testing | 1 | 2016 | 141 | 0.120 |
Why?
|
| Organic Cation Transport Proteins | 2 | 2008 | 13 | 0.120 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 65 | 0.120 |
Why?
|
| Netrin Receptors | 2 | 2014 | 7 | 0.120 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2013 | 32 | 0.120 |
Why?
|
| Proteolysis | 3 | 2012 | 124 | 0.120 |
Why?
|
| Sex Factors | 4 | 2020 | 1133 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 182 | 0.120 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2016 | 7 | 0.120 |
Why?
|
| Cathepsin L | 1 | 2016 | 7 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 3 | 2012 | 354 | 0.120 |
Why?
|
| Subcellular Fractions | 2 | 2007 | 95 | 0.120 |
Why?
|
| A549 Cells | 1 | 2016 | 51 | 0.120 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 19 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2012 | 152 | 0.120 |
Why?
|
| Stress, Physiological | 2 | 2017 | 252 | 0.120 |
Why?
|
| Monitoring, Immunologic | 2 | 2014 | 19 | 0.120 |
Why?
|
| Cystatin C | 1 | 2016 | 29 | 0.120 |
Why?
|
| Mice, Transgenic | 6 | 2024 | 1645 | 0.120 |
Why?
|
| Chromosome Deletion | 2 | 2015 | 229 | 0.120 |
Why?
|
| Vinblastine | 2 | 2007 | 100 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2017 | 123 | 0.120 |
Why?
|
| Glycolysis | 1 | 2017 | 191 | 0.120 |
Why?
|
| Plasma Cells | 1 | 2016 | 88 | 0.120 |
Why?
|
| Polyneuropathies | 1 | 2016 | 26 | 0.120 |
Why?
|
| Solubility | 2 | 2015 | 190 | 0.120 |
Why?
|
| Recombination, Genetic | 3 | 2024 | 444 | 0.120 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.120 |
Why?
|
| Receptor, EphA4 | 2 | 2006 | 5 | 0.120 |
Why?
|
| Chromatography, Liquid | 3 | 2011 | 104 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2015 | 73 | 0.120 |
Why?
|
| Myocarditis | 1 | 2016 | 58 | 0.120 |
Why?
|
| Ipilimumab | 1 | 2016 | 64 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 305 | 0.120 |
Why?
|
| Shoulder | 1 | 2016 | 43 | 0.120 |
Why?
|
| Heat-Shock Proteins | 1 | 2017 | 184 | 0.120 |
Why?
|
| Cause of Death | 4 | 2017 | 278 | 0.120 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2005 | 20 | 0.120 |
Why?
|
| Urothelium | 1 | 2016 | 69 | 0.120 |
Why?
|
| Plasmids | 6 | 2007 | 291 | 0.120 |
Why?
|
| Ribonucleotide Reductases | 2 | 2007 | 6 | 0.120 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2015 | 21 | 0.120 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2015 | 11 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2013 | 102 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2014 | 1010 | 0.120 |
Why?
|
| Incidence | 6 | 2019 | 1715 | 0.120 |
Why?
|
| Protein Stability | 2 | 2017 | 106 | 0.120 |
Why?
|
| Sarcoma, Ewing | 3 | 2005 | 43 | 0.120 |
Why?
|
| Kidney Transplantation | 2 | 2016 | 882 | 0.120 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 25 | 0.110 |
Why?
|
| Methotrexate | 2 | 2007 | 249 | 0.110 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 97 | 0.110 |
Why?
|
| Pupil Disorders | 1 | 2015 | 3 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2007 | 366 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2015 | 99 | 0.110 |
Why?
|
| Glypicans | 3 | 2011 | 7 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2016 | 304 | 0.110 |
Why?
|
| Drug Stability | 1 | 2015 | 50 | 0.110 |
Why?
|
| Urologic Neoplasms | 1 | 2016 | 78 | 0.110 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2018 | 463 | 0.110 |
Why?
|
| Pyridazines | 1 | 2015 | 22 | 0.110 |
Why?
|
| Pedigree | 5 | 2015 | 982 | 0.110 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2016 | 98 | 0.110 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2016 | 121 | 0.110 |
Why?
|
| Receptors, Androgen | 3 | 2010 | 120 | 0.110 |
Why?
|
| Age Factors | 6 | 2020 | 1963 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2016 | 121 | 0.110 |
Why?
|
| Serine Proteases | 1 | 2014 | 5 | 0.110 |
Why?
|
| Iron | 1 | 2015 | 179 | 0.110 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2014 | 30 | 0.110 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 3 | 2003 | 32 | 0.110 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2014 | 9 | 0.110 |
Why?
|
| In Situ Hybridization | 3 | 2005 | 312 | 0.110 |
Why?
|
| Adaptor Protein Complex delta Subunits | 1 | 2014 | 1 | 0.110 |
Why?
|
| Killer Cells, Natural | 2 | 2009 | 294 | 0.110 |
Why?
|
| Adaptor Protein Complex 3 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2014 | 10 | 0.110 |
Why?
|
| Bevacizumab | 3 | 2024 | 275 | 0.110 |
Why?
|
| GTP-Binding Proteins | 3 | 2011 | 148 | 0.110 |
Why?
|
| Liposomes | 1 | 2014 | 99 | 0.110 |
Why?
|
| GATA Transcription Factors | 1 | 2014 | 4 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 327 | 0.110 |
Why?
|
| Molecular Epidemiology | 2 | 2011 | 58 | 0.110 |
Why?
|
| Registries | 2 | 2017 | 986 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2011 | 38 | 0.110 |
Why?
|
| Receptors, Interleukin-17 | 2 | 2012 | 10 | 0.110 |
Why?
|
| Pleural Neoplasms | 2 | 2008 | 205 | 0.110 |
Why?
|
| Vaccines, Combined | 1 | 2014 | 6 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 107 | 0.110 |
Why?
|
| Machine Learning | 1 | 2017 | 348 | 0.110 |
Why?
|
| Allografts | 1 | 2015 | 207 | 0.110 |
Why?
|
| Hepatitis B | 2 | 2012 | 82 | 0.110 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2004 | 41 | 0.110 |
Why?
|
| Smad7 Protein | 1 | 2014 | 8 | 0.110 |
Why?
|
| Graves Disease | 2 | 2011 | 36 | 0.110 |
Why?
|
| Minisatellite Repeats | 4 | 2012 | 24 | 0.110 |
Why?
|
| Dysostoses | 1 | 2013 | 1 | 0.110 |
Why?
|
| RNA Stability | 4 | 2007 | 97 | 0.100 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2013 | 13 | 0.100 |
Why?
|
| Indazoles | 1 | 2014 | 61 | 0.100 |
Why?
|
| Hydro-Lyases | 2 | 2015 | 7 | 0.100 |
Why?
|
| Receptors, Ghrelin | 2 | 2011 | 5 | 0.100 |
Why?
|
| Sequence Alignment | 4 | 2014 | 360 | 0.100 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2013 | 23 | 0.100 |
Why?
|
| Adnexa Uteri | 1 | 2013 | 11 | 0.100 |
Why?
|
| ABO Blood-Group System | 3 | 2021 | 60 | 0.100 |
Why?
|
| Torsades de Pointes | 1 | 2013 | 7 | 0.100 |
Why?
|
| Transcriptome | 2 | 2017 | 769 | 0.100 |
Why?
|
| Autoantibodies | 3 | 2013 | 281 | 0.100 |
Why?
|
| Ramipril | 1 | 2013 | 2 | 0.100 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 206 | 0.100 |
Why?
|
| Angioedema | 1 | 2013 | 4 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 5 | 2013 | 110 | 0.100 |
Why?
|
| Telomerase | 2 | 2012 | 68 | 0.100 |
Why?
|
| Tumor Escape | 2 | 2015 | 53 | 0.100 |
Why?
|
| Hep G2 Cells | 4 | 2018 | 54 | 0.100 |
Why?
|
| Neuropeptide Y | 1 | 2013 | 31 | 0.100 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2013 | 39 | 0.100 |
Why?
|
| Carcinoma, Adenosquamous | 3 | 2014 | 12 | 0.100 |
Why?
|
| Neprilysin | 1 | 2013 | 41 | 0.100 |
Why?
|
| Rabbits | 7 | 2010 | 639 | 0.100 |
Why?
|
| Quality of Life | 2 | 2013 | 1816 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2011 | 61 | 0.100 |
Why?
|
| Lymphotoxin-alpha | 2 | 2004 | 43 | 0.100 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2004 | 52 | 0.100 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 48 | 0.100 |
Why?
|
| Thorax | 1 | 2013 | 80 | 0.100 |
Why?
|
| Malaysia | 4 | 2016 | 12 | 0.100 |
Why?
|
| Viral Load | 5 | 2011 | 164 | 0.100 |
Why?
|
| Stomach Ulcer | 1 | 2013 | 23 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2014 | 53 | 0.100 |
Why?
|
| Pelvis | 1 | 2013 | 103 | 0.100 |
Why?
|
| Interleukin-6 | 2 | 2014 | 281 | 0.100 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 411 | 0.100 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2013 | 69 | 0.100 |
Why?
|
| Receptor, Melanocortin, Type 4 | 2 | 2010 | 5 | 0.100 |
Why?
|
| HTLV-I Infections | 1 | 2013 | 5 | 0.100 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2013 | 11 | 0.100 |
Why?
|
| Catalogs as Topic | 2 | 2004 | 2 | 0.100 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2013 | 16 | 0.100 |
Why?
|
| Aromatase | 1 | 2013 | 12 | 0.100 |
Why?
|
| RNA, Viral | 5 | 2012 | 311 | 0.100 |
Why?
|
| Gluconeogenesis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2013 | 9 | 0.100 |
Why?
|
| Menarche | 1 | 2013 | 30 | 0.100 |
Why?
|
| Sp3 Transcription Factor | 1 | 2013 | 3 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 124 | 0.100 |
Why?
|
| Physical Chromosome Mapping | 1 | 2013 | 27 | 0.100 |
Why?
|
| Infant | 5 | 2012 | 3363 | 0.100 |
Why?
|
| Hydroxylation | 1 | 2013 | 19 | 0.100 |
Why?
|
| Molecular Conformation | 1 | 2013 | 111 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 98 | 0.100 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2013 | 6 | 0.100 |
Why?
|
| Protein Array Analysis | 2 | 2012 | 52 | 0.100 |
Why?
|
| Haptoglobins | 1 | 2012 | 9 | 0.100 |
Why?
|
| Glucose | 2 | 2013 | 701 | 0.100 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 23 | 0.100 |
Why?
|
| Untranslated Regions | 2 | 2003 | 18 | 0.100 |
Why?
|
| Testosterone | 2 | 2012 | 277 | 0.100 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2010 | 76 | 0.100 |
Why?
|
| Cell Membrane | 4 | 2016 | 695 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2017 | 873 | 0.100 |
Why?
|
| Methyltransferases | 1 | 2014 | 213 | 0.100 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2017 | 926 | 0.100 |
Why?
|
| Macular Degeneration | 1 | 2013 | 51 | 0.100 |
Why?
|
| Oligosaccharides | 1 | 2012 | 26 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 630 | 0.100 |
Why?
|
| Sarcoma | 2 | 2013 | 225 | 0.100 |
Why?
|
| I-kappa B Proteins | 1 | 2012 | 54 | 0.090 |
Why?
|
| Genes, APC | 2 | 2002 | 27 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2013 | 161 | 0.090 |
Why?
|
| Universities | 1 | 2013 | 154 | 0.090 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2012 | 3 | 0.090 |
Why?
|
| Calpain | 1 | 2013 | 113 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2017 | 591 | 0.090 |
Why?
|
| Histidine | 1 | 2013 | 75 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 34 | 0.090 |
Why?
|
| Body Height | 2 | 2010 | 108 | 0.090 |
Why?
|
| RNA, Ribosomal | 1 | 2012 | 72 | 0.090 |
Why?
|
| DNA Polymerase III | 1 | 2012 | 11 | 0.090 |
Why?
|
| Glycine Dehydrogenase | 1 | 2012 | 1 | 0.090 |
Why?
|
| Hypertension | 2 | 2009 | 774 | 0.090 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2012 | 39 | 0.090 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 922 | 0.090 |
Why?
|
| Hysterectomy | 1 | 2013 | 168 | 0.090 |
Why?
|
| Annexin A4 | 1 | 2012 | 2 | 0.090 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2012 | 27 | 0.090 |
Why?
|
| DCC Receptor | 1 | 2012 | 4 | 0.090 |
Why?
|
| Gout | 1 | 2012 | 75 | 0.090 |
Why?
|
| Lentivirus | 2 | 2009 | 44 | 0.090 |
Why?
|
| Caspase 3 | 2 | 2010 | 164 | 0.090 |
Why?
|
| Ankyrins | 1 | 2012 | 23 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1267 | 0.090 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 11 | 0.090 |
Why?
|
| Transaminases | 1 | 2012 | 34 | 0.090 |
Why?
|
| Atherosclerosis | 3 | 2010 | 267 | 0.090 |
Why?
|
| Sensory Receptor Cells | 1 | 2012 | 39 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 85 | 0.090 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 48 | 0.090 |
Why?
|
| Jurkat Cells | 6 | 2009 | 83 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 294 | 0.090 |
Why?
|
| Microarray Analysis | 4 | 2017 | 98 | 0.090 |
Why?
|
| Drug Hypersensitivity | 2 | 2009 | 40 | 0.090 |
Why?
|
| Megakaryocytes | 1 | 2011 | 39 | 0.090 |
Why?
|
| Zimbabwe | 1 | 2011 | 3 | 0.090 |
Why?
|
| Chemokine CCL22 | 1 | 2011 | 8 | 0.090 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2011 | 6 | 0.090 |
Why?
|
| Reference Values | 3 | 2012 | 674 | 0.090 |
Why?
|
| Glycine | 1 | 2012 | 96 | 0.090 |
Why?
|
| Epirubicin | 1 | 2011 | 14 | 0.090 |
Why?
|
| Cyclopropanes | 1 | 2011 | 27 | 0.090 |
Why?
|
| HLA-B52 Antigen | 1 | 2011 | 1 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 432 | 0.090 |
Why?
|
| Lamivudine | 1 | 2011 | 13 | 0.090 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2010 | 9 | 0.090 |
Why?
|
| Aurora Kinases | 2 | 2012 | 19 | 0.090 |
Why?
|
| Alkynes | 1 | 2011 | 21 | 0.090 |
Why?
|
| Aurora Kinase B | 2 | 2012 | 16 | 0.090 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 527 | 0.090 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2010 | 49 | 0.090 |
Why?
|
| China | 4 | 2014 | 264 | 0.090 |
Why?
|
| HLA-C Antigens | 1 | 2011 | 18 | 0.090 |
Why?
|
| Microsatellite Repeats | 3 | 2017 | 151 | 0.090 |
Why?
|
| Wet Macular Degeneration | 1 | 2011 | 22 | 0.090 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 3 | 2020 | 41 | 0.090 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 1 | 2011 | 2 | 0.090 |
Why?
|
| Ghrelin | 1 | 2011 | 29 | 0.090 |
Why?
|
| Enzymes | 1 | 2011 | 47 | 0.090 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1179 | 0.090 |
Why?
|
| HLA-DQ Antigens | 1 | 2011 | 52 | 0.090 |
Why?
|
| Sequence Deletion | 1 | 2012 | 212 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2011 | 54 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 151 | 0.090 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2008 | 114 | 0.090 |
Why?
|
| Cell Extracts | 1 | 2011 | 15 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2011 | 156 | 0.090 |
Why?
|
| Nephrotic Syndrome | 1 | 2011 | 33 | 0.090 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2011 | 14 | 0.090 |
Why?
|
| Gastric Mucosa | 1 | 2011 | 70 | 0.080 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2010 | 9 | 0.080 |
Why?
|
| Paroxetine | 1 | 2011 | 26 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2018 | 1791 | 0.080 |
Why?
|
| Gene Products, tax | 1 | 2010 | 3 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 36 | 0.080 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2010 | 1 | 0.080 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 2 | 2013 | 7 | 0.080 |
Why?
|
| Calcium | 2 | 2013 | 1205 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 276 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2011 | 132 | 0.080 |
Why?
|
| Exonucleases | 1 | 2010 | 9 | 0.080 |
Why?
|
| Virus Replication | 4 | 2018 | 326 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2008 | 42 | 0.080 |
Why?
|
| Glycomics | 1 | 2010 | 2 | 0.080 |
Why?
|
| Glioblastoma | 2 | 2004 | 285 | 0.080 |
Why?
|
| Wnt Signaling Pathway | 1 | 2011 | 103 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2016 | 1126 | 0.080 |
Why?
|
| Gene Knockout Techniques | 3 | 2017 | 85 | 0.080 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2010 | 41 | 0.080 |
Why?
|
| Hematopoiesis | 1 | 2011 | 183 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2007 | 207 | 0.080 |
Why?
|
| Musculoskeletal System | 1 | 2010 | 16 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2010 | 58 | 0.080 |
Why?
|
| Collagen Type I | 1 | 2011 | 74 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2012 | 125 | 0.080 |
Why?
|
| Xedar Receptor | 1 | 2010 | 1 | 0.080 |
Why?
|
| Community Networks | 1 | 2010 | 32 | 0.080 |
Why?
|
| Ectodysplasins | 1 | 2010 | 5 | 0.080 |
Why?
|
| Pregnanediones | 1 | 2010 | 1 | 0.080 |
Why?
|
| Osteonectin | 1 | 2010 | 22 | 0.080 |
Why?
|
| Receptors, CCR6 | 1 | 2010 | 4 | 0.080 |
Why?
|
| Alpha Particles | 2 | 2021 | 4 | 0.080 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 1 | 2010 | 2 | 0.080 |
Why?
|
| Insulin | 2 | 2013 | 1190 | 0.080 |
Why?
|
| Intra-Abdominal Fat | 1 | 2010 | 34 | 0.080 |
Why?
|
| Recurrence | 3 | 2024 | 1218 | 0.080 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2012 | 27 | 0.080 |
Why?
|
| Metalloproteases | 1 | 2010 | 10 | 0.080 |
Why?
|
| E2F2 Transcription Factor | 1 | 2010 | 5 | 0.080 |
Why?
|
| Immunization, Passive | 1 | 2010 | 75 | 0.080 |
Why?
|
| Hemoglobin E | 1 | 2010 | 1 | 0.080 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 1 | 2010 | 1 | 0.080 |
Why?
|
| Chromosomes, Human | 3 | 2011 | 67 | 0.080 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 33 | 0.080 |
Why?
|
| Phospholipase C beta | 1 | 2010 | 2 | 0.080 |
Why?
|
| Lipodystrophy | 1 | 2010 | 3 | 0.080 |
Why?
|
| Pressoreceptors | 1 | 2010 | 12 | 0.080 |
Why?
|
| beta-Thalassemia | 1 | 2010 | 6 | 0.080 |
Why?
|
| Co-Repressor Proteins | 1 | 2010 | 25 | 0.080 |
Why?
|
| Solitary Nucleus | 1 | 2010 | 22 | 0.080 |
Why?
|
| Eye Proteins | 2 | 2015 | 130 | 0.080 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2011 | 144 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2011 | 287 | 0.080 |
Why?
|
| Leptin | 1 | 2010 | 102 | 0.080 |
Why?
|
| Psoriasis | 1 | 2013 | 254 | 0.080 |
Why?
|
| Aldosterone | 1 | 2010 | 56 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 62 | 0.080 |
Why?
|
| HLA Antigens | 3 | 2018 | 231 | 0.080 |
Why?
|
| Base Pairing | 1 | 2010 | 56 | 0.080 |
Why?
|
| Aldose-Ketose Isomerases | 1 | 2009 | 3 | 0.080 |
Why?
|
| Transcription Factor AP-2 | 2 | 2010 | 14 | 0.080 |
Why?
|
| cdc42 GTP-Binding Protein | 2 | 2010 | 12 | 0.080 |
Why?
|
| HMGB1 Protein | 1 | 2009 | 19 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 1 | 2010 | 35 | 0.080 |
Why?
|
| Biometry | 1 | 2010 | 72 | 0.080 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2009 | 31 | 0.080 |
Why?
|
| Wnt Proteins | 5 | 2010 | 131 | 0.080 |
Why?
|
| Sirtuins | 1 | 2011 | 80 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2011 | 179 | 0.080 |
Why?
|
| Forensic Medicine | 1 | 2009 | 7 | 0.080 |
Why?
|
| Cell Communication | 1 | 2011 | 221 | 0.080 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2010 | 60 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 271 | 0.080 |
Why?
|
| International Cooperation | 1 | 2010 | 134 | 0.080 |
Why?
|
| Interleukin-18 | 1 | 2009 | 29 | 0.080 |
Why?
|
| Home Care Services | 1 | 2010 | 77 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 212 | 0.080 |
Why?
|
| Interleukin-12 | 2 | 2012 | 116 | 0.080 |
Why?
|
| Acetyltransferases | 1 | 2009 | 36 | 0.080 |
Why?
|
| Genes | 1 | 2010 | 308 | 0.080 |
Why?
|
| Protein Conformation | 2 | 2021 | 935 | 0.080 |
Why?
|
| Imatinib Mesylate | 3 | 2007 | 127 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 5 | 2005 | 147 | 0.080 |
Why?
|
| Adenoviridae | 6 | 2008 | 342 | 0.080 |
Why?
|
| Centromere | 1 | 2009 | 27 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 116 | 0.080 |
Why?
|
| Anaphylaxis | 1 | 2009 | 33 | 0.080 |
Why?
|
| Group II Chaperonins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 326 | 0.080 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2009 | 24 | 0.080 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2009 | 81 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2013 | 464 | 0.070 |
Why?
|
| Castration | 1 | 2009 | 37 | 0.070 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 27 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2011 | 255 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2011 | 369 | 0.070 |
Why?
|
| Selection, Genetic | 3 | 2007 | 537 | 0.070 |
Why?
|
| Semaphorins | 2 | 2006 | 18 | 0.070 |
Why?
|
| Integrins | 1 | 2009 | 79 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2009 | 13 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2009 | 12 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 1 | 2010 | 163 | 0.070 |
Why?
|
| Eukaryotic Cells | 1 | 2009 | 44 | 0.070 |
Why?
|
| Premenopause | 1 | 2009 | 63 | 0.070 |
Why?
|
| Comorbidity | 3 | 2017 | 1011 | 0.070 |
Why?
|
| Sendai virus | 1 | 2008 | 8 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 363 | 0.070 |
Why?
|
| Osteonecrosis | 1 | 2008 | 21 | 0.070 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2009 | 243 | 0.070 |
Why?
|
| Androstadienes | 3 | 2014 | 74 | 0.070 |
Why?
|
| Fatty Acids | 1 | 2009 | 153 | 0.070 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2009 | 179 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 199 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2013 | 441 | 0.070 |
Why?
|
| Schizosaccharomyces | 1 | 2009 | 56 | 0.070 |
Why?
|
| STAT4 Transcription Factor | 1 | 2008 | 10 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 62 | 0.070 |
Why?
|
| Neurons | 3 | 2015 | 1653 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 1876 | 0.070 |
Why?
|
| Benzamides | 3 | 2007 | 248 | 0.070 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2009 | 57 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 206 | 0.070 |
Why?
|
| Palliative Care | 1 | 2010 | 273 | 0.070 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2008 | 22 | 0.070 |
Why?
|
| Rhabdomyolysis | 1 | 2008 | 28 | 0.070 |
Why?
|
| Intraoperative Care | 2 | 2019 | 89 | 0.070 |
Why?
|
| RGS Proteins | 1 | 2008 | 19 | 0.070 |
Why?
|
| Neutrophils | 1 | 2010 | 332 | 0.070 |
Why?
|
| Toll-Like Receptors | 2 | 2006 | 101 | 0.070 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2008 | 14 | 0.070 |
Why?
|
| Solute Carrier Organic Anion Transporter Family Member 1B3 | 1 | 2008 | 4 | 0.070 |
Why?
|
| Food Hypersensitivity | 1 | 2009 | 80 | 0.070 |
Why?
|
| Chondrogenesis | 2 | 2005 | 32 | 0.070 |
Why?
|
| Oxidative Stress | 3 | 2012 | 473 | 0.070 |
Why?
|
| Chondrocytes | 2 | 2010 | 66 | 0.070 |
Why?
|
| Nerve Growth Factors | 2 | 2005 | 61 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Alternative Splicing | 5 | 2008 | 220 | 0.070 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2008 | 17 | 0.070 |
Why?
|
| Syndrome | 1 | 2009 | 453 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2010 | 307 | 0.070 |
Why?
|
| Anxiety | 1 | 2010 | 339 | 0.070 |
Why?
|
| Coronary Aneurysm | 1 | 2007 | 16 | 0.070 |
Why?
|
| GABA Agents | 1 | 2007 | 8 | 0.070 |
Why?
|
| G2 Phase | 1 | 2007 | 33 | 0.070 |
Why?
|
| Republic of Korea | 3 | 2014 | 36 | 0.070 |
Why?
|
| Tubulin | 2 | 2005 | 61 | 0.070 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2007 | 6 | 0.070 |
Why?
|
| Receptors, GABA-A | 1 | 2007 | 35 | 0.070 |
Why?
|
| Nitrobenzenes | 1 | 2007 | 12 | 0.070 |
Why?
|
| Neurocalcin | 1 | 2007 | 2 | 0.070 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Survivors | 1 | 2009 | 204 | 0.070 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2006 | 21 | 0.070 |
Why?
|
| National Health Programs | 1 | 2007 | 19 | 0.070 |
Why?
|
| Precipitin Tests | 2 | 2004 | 108 | 0.070 |
Why?
|
| Angiogenic Proteins | 1 | 2007 | 17 | 0.070 |
Why?
|
| Genes, Dominant | 3 | 2015 | 116 | 0.070 |
Why?
|
| Proteoglycans | 2 | 2005 | 126 | 0.070 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2007 | 81 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 2009 | 178 | 0.070 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2011 | 292 | 0.070 |
Why?
|
| Laminin | 2 | 2004 | 92 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2008 | 148 | 0.070 |
Why?
|
| Symporters | 2 | 2008 | 112 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2007 | 87 | 0.070 |
Why?
|
| Behavior, Animal | 1 | 2010 | 394 | 0.070 |
Why?
|
| Receptors, Interleukin | 1 | 2007 | 39 | 0.070 |
Why?
|
| Mitochondrial Diseases | 1 | 2007 | 12 | 0.070 |
Why?
|
| Atrial Fibrillation | 1 | 2012 | 392 | 0.070 |
Why?
|
| Alpha-Globulins | 1 | 2007 | 11 | 0.060 |
Why?
|
| Chromogranins | 1 | 2007 | 11 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 183 | 0.060 |
Why?
|
| Gene Duplication | 1 | 2008 | 129 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2023 | 983 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2007 | 85 | 0.060 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 481 | 0.060 |
Why?
|
| Brain Infarction | 1 | 2007 | 24 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 170 | 0.060 |
Why?
|
| Opisthorchis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Receptors, Neurotensin | 1 | 2006 | 3 | 0.060 |
Why?
|
| Toxoplasma | 1 | 2007 | 120 | 0.060 |
Why?
|
| Inflammation | 2 | 2010 | 1063 | 0.060 |
Why?
|
| Genome, Viral | 2 | 2020 | 80 | 0.060 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2006 | 11 | 0.060 |
Why?
|
| Autoimmunity | 2 | 2005 | 192 | 0.060 |
Why?
|
| Biopsy, Needle | 3 | 2018 | 231 | 0.060 |
Why?
|
| Secretory Vesicles | 1 | 2007 | 43 | 0.060 |
Why?
|
| Asia | 3 | 2012 | 105 | 0.060 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 16 | 0.060 |
Why?
|
| CDC2 Protein Kinase | 3 | 2014 | 47 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2006 | 63 | 0.060 |
Why?
|
| Cerebral Infarction | 1 | 2007 | 74 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2007 | 197 | 0.060 |
Why?
|
| Chemokines, CC | 1 | 2006 | 37 | 0.060 |
Why?
|
| Chemistry, Physical | 1 | 2006 | 29 | 0.060 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2006 | 1 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2006 | 84 | 0.060 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 132 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 3 | 2013 | 24 | 0.060 |
Why?
|
| Cytochrome c Group | 2 | 2003 | 82 | 0.060 |
Why?
|
| Silicon | 1 | 2006 | 20 | 0.060 |
Why?
|
| Cerumen | 1 | 2006 | 3 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2005 | 224 | 0.060 |
Why?
|
| Hypersensitivity | 1 | 2007 | 166 | 0.060 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2006 | 9 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 84 | 0.060 |
Why?
|
| EGF Family of Proteins | 1 | 2005 | 3 | 0.060 |
Why?
|
| Transplantation, Heterologous | 2 | 2007 | 376 | 0.060 |
Why?
|
| Adoptive Transfer | 2 | 2021 | 175 | 0.060 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2006 | 65 | 0.060 |
Why?
|
| Ultraviolet Rays | 5 | 2006 | 198 | 0.060 |
Why?
|
| Amphiregulin | 1 | 2005 | 15 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2012 | 908 | 0.060 |
Why?
|
| Plakophilins | 1 | 2005 | 4 | 0.060 |
Why?
|
| Esophagus | 1 | 2006 | 111 | 0.060 |
Why?
|
| Diabetes Complications | 2 | 2017 | 175 | 0.060 |
Why?
|
| Biopolymers | 1 | 2005 | 28 | 0.060 |
Why?
|
| Histone Chaperones | 1 | 2005 | 2 | 0.060 |
Why?
|
| Confidentiality | 1 | 2005 | 79 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 223 | 0.060 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2005 | 15 | 0.060 |
Why?
|
| Laser Capture Microdissection | 2 | 2017 | 20 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2018 | 819 | 0.060 |
Why?
|
| Chaperonins | 1 | 2005 | 10 | 0.060 |
Why?
|
| Catenins | 1 | 2005 | 11 | 0.060 |
Why?
|
| Single-Chain Antibodies | 1 | 2025 | 21 | 0.060 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2005 | 8 | 0.060 |
Why?
|
| Hyperphagia | 1 | 2005 | 35 | 0.060 |
Why?
|
| Calcineurin Inhibitors | 1 | 2005 | 53 | 0.060 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2005 | 48 | 0.060 |
Why?
|
| Urea | 1 | 2005 | 60 | 0.060 |
Why?
|
| Caspase 9 | 1 | 2005 | 49 | 0.060 |
Why?
|
| Caspase Inhibitors | 1 | 2005 | 32 | 0.060 |
Why?
|
| Leucine | 2 | 2020 | 62 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2018 | 226 | 0.060 |
Why?
|
| Serology | 1 | 2004 | 3 | 0.060 |
Why?
|
| Biopsy | 1 | 2009 | 1220 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2004 | 11 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2025 | 136 | 0.060 |
Why?
|
| Dynamins | 1 | 2005 | 50 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2006 | 128 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2011 | 340 | 0.060 |
Why?
|
| GTP Phosphohydrolases | 1 | 2005 | 82 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2004 | 41 | 0.060 |
Why?
|
| Citrulline | 3 | 2012 | 10 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 3 | 2012 | 141 | 0.060 |
Why?
|
| Osteogenesis | 2 | 2004 | 277 | 0.060 |
Why?
|
| Histone Deacetylase 1 | 1 | 2004 | 16 | 0.060 |
Why?
|
| E2F Transcription Factors | 1 | 2004 | 21 | 0.060 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2005 | 50 | 0.060 |
Why?
|
| Empyema, Pleural | 1 | 2004 | 11 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2006 | 433 | 0.060 |
Why?
|
| Microdissection | 1 | 2004 | 18 | 0.060 |
Why?
|
| Automation | 1 | 2025 | 115 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2004 | 39 | 0.050 |
Why?
|
| Metabolomics | 2 | 2018 | 98 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2005 | 242 | 0.050 |
Why?
|
| Consensus Sequence | 3 | 2016 | 67 | 0.050 |
Why?
|
| Pancreatitis-Associated Proteins | 3 | 2009 | 18 | 0.050 |
Why?
|
| Culture Media | 1 | 2004 | 150 | 0.050 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2004 | 40 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2004 | 77 | 0.050 |
Why?
|
| Galectin 2 | 1 | 2004 | 2 | 0.050 |
Why?
|
| Marfan Syndrome | 1 | 2004 | 28 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 311 | 0.050 |
Why?
|
| Lupus Nephritis | 1 | 2005 | 79 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 187 | 0.050 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2004 | 52 | 0.050 |
Why?
|
| Pancreatic Ducts | 1 | 2004 | 30 | 0.050 |
Why?
|
| RNA Polymerase II | 1 | 2004 | 62 | 0.050 |
Why?
|
| Ifosfamide | 1 | 2004 | 48 | 0.050 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2024 | 65 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2005 | 373 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2004 | 57 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2004 | 96 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 127 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2014 | 72 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 4 | 2007 | 445 | 0.050 |
Why?
|
| Small Molecule Libraries | 2 | 2016 | 69 | 0.050 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2003 | 9 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2004 | 71 | 0.050 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2003 | 17 | 0.050 |
Why?
|
| Mice, Inbred ICR | 1 | 2004 | 77 | 0.050 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2003 | 11 | 0.050 |
Why?
|
| NIMA-Related Kinases | 2 | 2014 | 7 | 0.050 |
Why?
|
| Organ of Corti | 1 | 2003 | 10 | 0.050 |
Why?
|
| Hyperthermia, Induced | 1 | 2004 | 75 | 0.050 |
Why?
|
| Transcription Factor 4 | 1 | 2003 | 13 | 0.050 |
Why?
|
| T-Box Domain Proteins | 1 | 2005 | 128 | 0.050 |
Why?
|
| Receptors, Vasopressin | 1 | 2003 | 7 | 0.050 |
Why?
|
| Electron Transport Complex IV | 1 | 2003 | 49 | 0.050 |
Why?
|
| Receptors, Prostaglandin | 1 | 2003 | 7 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2003 | 6 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2004 | 215 | 0.050 |
Why?
|
| Deoxyribonucleotides | 1 | 2003 | 8 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2019 | 60 | 0.050 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2003 | 6 | 0.050 |
Why?
|
| Receptors, Dopamine | 1 | 2003 | 37 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2013 | 935 | 0.050 |
Why?
|
| Esters | 1 | 2023 | 31 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2004 | 59 | 0.050 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2003 | 21 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 90 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 15 | 0.050 |
Why?
|
| Darbepoetin alfa | 1 | 2023 | 5 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2003 | 60 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 218 | 0.050 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2003 | 17 | 0.050 |
Why?
|
| Cyclin E | 1 | 2003 | 28 | 0.050 |
Why?
|
| Wound Healing | 1 | 2005 | 378 | 0.050 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2003 | 19 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2003 | 37 | 0.050 |
Why?
|
| Biotransformation | 2 | 2014 | 49 | 0.050 |
Why?
|
| F-Box Proteins | 1 | 2003 | 14 | 0.050 |
Why?
|
| Scleroproteins | 1 | 2003 | 1 | 0.050 |
Why?
|
| Herpes Simplex | 1 | 2004 | 203 | 0.050 |
Why?
|
| Muscular Dystrophies | 1 | 2003 | 55 | 0.050 |
Why?
|
| Bacteriophage T7 | 1 | 2003 | 7 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2003 | 101 | 0.050 |
Why?
|
| Informed Consent | 1 | 2005 | 281 | 0.050 |
Why?
|
| Quality Control | 2 | 2014 | 125 | 0.050 |
Why?
|
| Lymphoma | 1 | 2004 | 271 | 0.050 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2002 | 8 | 0.050 |
Why?
|
| Menstrual Cycle | 1 | 2003 | 59 | 0.050 |
Why?
|
| Eye | 1 | 2003 | 112 | 0.050 |
Why?
|
| Postural Balance | 1 | 2003 | 52 | 0.050 |
Why?
|
| Tunica Intima | 1 | 2003 | 61 | 0.050 |
Why?
|
| Gene-Environment Interaction | 2 | 2014 | 120 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2002 | 17 | 0.050 |
Why?
|
| NADP | 1 | 2002 | 49 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2003 | 74 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2013 | 79 | 0.050 |
Why?
|
| Chromosome Inversion | 1 | 2002 | 48 | 0.050 |
Why?
|
| Femoral Artery | 1 | 2003 | 91 | 0.050 |
Why?
|
| Carbocyanines | 1 | 2002 | 18 | 0.050 |
Why?
|
| Bone Density | 2 | 2014 | 239 | 0.050 |
Why?
|
| Hearing | 1 | 2003 | 64 | 0.050 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2012 | 21 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2002 | 116 | 0.050 |
Why?
|
| Glomerulonephritis | 1 | 2003 | 80 | 0.050 |
Why?
|
| Golgi Apparatus | 2 | 2017 | 117 | 0.050 |
Why?
|
| CHO Cells | 3 | 2008 | 196 | 0.050 |
Why?
|
| Glycerophosphates | 1 | 2002 | 5 | 0.050 |
Why?
|
| Genes, MDR | 1 | 2002 | 7 | 0.050 |
Why?
|
| HLA-DR alpha-Chains | 1 | 2002 | 4 | 0.050 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2002 | 38 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2003 | 219 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2022 | 46 | 0.050 |
Why?
|
| Ossification of Posterior Longitudinal Ligament | 1 | 2002 | 2 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2002 | 61 | 0.050 |
Why?
|
| Trinucleotide Repeats | 1 | 2002 | 30 | 0.050 |
Why?
|
| Osteoblasts | 1 | 2002 | 98 | 0.050 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2002 | 24 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2002 | 90 | 0.050 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2002 | 39 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 33 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2022 | 65 | 0.050 |
Why?
|
| X Chromosome | 1 | 2002 | 157 | 0.050 |
Why?
|
| Salivary Ducts | 1 | 2021 | 6 | 0.040 |
Why?
|
| Epithelium | 3 | 2008 | 322 | 0.040 |
Why?
|
| RNA Splicing | 2 | 2017 | 159 | 0.040 |
Why?
|
| Singapore | 2 | 2014 | 15 | 0.040 |
Why?
|
| Platelet Count | 2 | 2011 | 97 | 0.040 |
Why?
|
| Long QT Syndrome | 1 | 2002 | 39 | 0.040 |
Why?
|
| Mass Screening | 2 | 2021 | 710 | 0.040 |
Why?
|
| Protein Biosynthesis | 3 | 2012 | 399 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2005 | 363 | 0.040 |
Why?
|
| Cricetinae | 3 | 2008 | 542 | 0.040 |
Why?
|
| ras Proteins | 1 | 2002 | 134 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2024 | 246 | 0.040 |
Why?
|
| Gene Components | 2 | 2015 | 7 | 0.040 |
Why?
|
| Genetic Pleiotropy | 1 | 2021 | 29 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 111 | 0.040 |
Why?
|
| Forecasting | 1 | 2002 | 317 | 0.040 |
Why?
|
| Bayes Theorem | 2 | 2014 | 404 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 2 | 2017 | 264 | 0.040 |
Why?
|
| Intellectual Disability | 1 | 2002 | 203 | 0.040 |
Why?
|
| Neurodegenerative Diseases | 1 | 2002 | 58 | 0.040 |
Why?
|
| Freund's Adjuvant | 2 | 2012 | 27 | 0.040 |
Why?
|
| Fetus | 1 | 2002 | 239 | 0.040 |
Why?
|
| Age Distribution | 2 | 2012 | 209 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2020 | 27 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2002 | 192 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 482 | 0.040 |
Why?
|
| HLA-DP alpha-Chains | 2 | 2011 | 5 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 109 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 134 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 45 | 0.040 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2002 | 88 | 0.040 |
Why?
|
| HLA-DP beta-Chains | 2 | 2011 | 8 | 0.040 |
Why?
|
| Pregnancy | 2 | 2007 | 3240 | 0.040 |
Why?
|
| tRNA Methyltransferases | 2 | 2012 | 14 | 0.040 |
Why?
|
| Ion Channels | 1 | 2002 | 260 | 0.040 |
Why?
|
| Inheritance Patterns | 1 | 2020 | 52 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 26 | 0.040 |
Why?
|
| Gene Amplification | 2 | 2011 | 143 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2002 | 351 | 0.040 |
Why?
|
| Disease Models, Animal | 4 | 2011 | 2534 | 0.040 |
Why?
|
| Fetal Proteins | 1 | 2019 | 19 | 0.040 |
Why?
|
| Drug Design | 2 | 2012 | 133 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 483 | 0.040 |
Why?
|
| Waist-Hip Ratio | 2 | 2010 | 21 | 0.040 |
Why?
|
| Chimerism | 1 | 2020 | 38 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2010 | 80 | 0.040 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2019 | 30 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 264 | 0.040 |
Why?
|
| Tumor Protein p73 | 3 | 2005 | 6 | 0.040 |
Why?
|
| Brain Chemistry | 1 | 2020 | 120 | 0.040 |
Why?
|
| Epigenomics | 1 | 2020 | 109 | 0.040 |
Why?
|
| Korea | 2 | 2010 | 18 | 0.040 |
Why?
|
| Orchiectomy | 2 | 2010 | 63 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 83 | 0.040 |
Why?
|
| Biological Transport | 2 | 2011 | 412 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 677 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2023 | 514 | 0.040 |
Why?
|
| Intestines | 1 | 2002 | 431 | 0.040 |
Why?
|
| Immunoblotting | 3 | 2005 | 280 | 0.040 |
Why?
|
| DNA Fingerprinting | 2 | 2009 | 18 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 69 | 0.040 |
Why?
|
| Age of Onset | 2 | 2015 | 344 | 0.040 |
Why?
|
| Containment of Biohazards | 1 | 2019 | 8 | 0.040 |
Why?
|
| Hydrogen Peroxide | 2 | 2014 | 165 | 0.040 |
Why?
|
| Intermediate Filament Proteins | 2 | 2013 | 35 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 372 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 317 | 0.040 |
Why?
|
| Frozen Sections | 1 | 2019 | 50 | 0.040 |
Why?
|
| Cyclin B1 | 2 | 2009 | 17 | 0.040 |
Why?
|
| Antiporters | 2 | 2009 | 18 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 509 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2006 | 1030 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2011 | 302 | 0.040 |
Why?
|
| Computer Simulation | 3 | 2008 | 1158 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 427 | 0.040 |
Why?
|
| Enzyme Stability | 1 | 2018 | 41 | 0.040 |
Why?
|
| Heart | 1 | 2002 | 591 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 213 | 0.040 |
Why?
|
| Genes, Neoplasm | 2 | 2010 | 39 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 117 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2019 | 109 | 0.040 |
Why?
|
| Necrosis | 1 | 2018 | 210 | 0.040 |
Why?
|
| Poly I-C | 2 | 2008 | 19 | 0.040 |
Why?
|
| Citrullination | 1 | 2018 | 1 | 0.040 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2018 | 3 | 0.040 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2018 | 9 | 0.030 |
Why?
|
| Immunization | 1 | 2018 | 165 | 0.030 |
Why?
|
| Protein Aggregates | 1 | 2018 | 28 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 1319 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2018 | 123 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 938 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 383 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2018 | 120 | 0.030 |
Why?
|
| Cysteine | 1 | 2018 | 146 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2020 | 514 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 1023 | 0.030 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2017 | 8 | 0.030 |
Why?
|
| Cricetulus | 2 | 2008 | 132 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 35 | 0.030 |
Why?
|
| Genetic Research | 1 | 2017 | 18 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.030 |
Why?
|
| United States | 1 | 2010 | 7768 | 0.030 |
Why?
|
| Pancreatectomy | 2 | 2009 | 168 | 0.030 |
Why?
|
| Hypothalamus | 2 | 2007 | 80 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 2017 | 49 | 0.030 |
Why?
|
| Visual Cortex | 1 | 2020 | 265 | 0.030 |
Why?
|
| Perforin | 1 | 2016 | 56 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2016 | 82 | 0.030 |
Why?
|
| Immunoglobulin E | 2 | 2009 | 152 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 93 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2017 | 88 | 0.030 |
Why?
|
| Prevalence | 2 | 2012 | 1349 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 438 | 0.030 |
Why?
|
| Tyrosine | 1 | 2016 | 132 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2007 | 45 | 0.030 |
Why?
|
| Mucin-4 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2016 | 110 | 0.030 |
Why?
|
| Telomere | 1 | 2017 | 121 | 0.030 |
Why?
|
| Lod Score | 2 | 2007 | 153 | 0.030 |
Why?
|
| Vitamin D | 1 | 2018 | 273 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 245 | 0.030 |
Why?
|
| Iron Regulatory Protein 1 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Bystander Effect | 1 | 2015 | 14 | 0.030 |
Why?
|
| RNA Isoforms | 1 | 2015 | 5 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2015 | 38 | 0.030 |
Why?
|
| Threonine | 1 | 2015 | 34 | 0.030 |
Why?
|
| Ferritins | 1 | 2015 | 31 | 0.030 |
Why?
|
| Cross-Priming | 1 | 2015 | 54 | 0.030 |
Why?
|
| Ileum | 1 | 2016 | 169 | 0.030 |
Why?
|
| Prednisone | 1 | 2016 | 258 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2015 | 8 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 188 | 0.030 |
Why?
|
| Pharmacogenomic Testing | 1 | 2016 | 107 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 40 | 0.030 |
Why?
|
| Dimerization | 2 | 2006 | 150 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 40 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 259 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 299 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 53 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 79 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2014 | 32 | 0.030 |
Why?
|
| Interleukin-4 | 2 | 2006 | 136 | 0.030 |
Why?
|
| Mediastinum | 1 | 2014 | 48 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 1010 | 0.030 |
Why?
|
| Toremifene | 1 | 2014 | 1 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 71 | 0.030 |
Why?
|
| Enzyme Activators | 1 | 2014 | 15 | 0.030 |
Why?
|
| Probability | 2 | 2008 | 365 | 0.030 |
Why?
|
| Cell Separation | 1 | 2014 | 205 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2016 | 339 | 0.030 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2014 | 8 | 0.030 |
Why?
|
| RNA Splicing Factors | 1 | 2014 | 30 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2014 | 42 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 108 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 880 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 100 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 150 | 0.030 |
Why?
|
| Protein Kinase C-theta | 1 | 2013 | 16 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2014 | 104 | 0.030 |
Why?
|
| Drosophila Proteins | 2 | 2011 | 523 | 0.030 |
Why?
|
| Dissection | 2 | 2005 | 45 | 0.030 |
Why?
|
| Celecoxib | 1 | 2013 | 33 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2012 | 2614 | 0.030 |
Why?
|
| Benzoates | 1 | 2013 | 33 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 2 | 2004 | 41 | 0.030 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2013 | 10 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 108 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2013 | 333 | 0.030 |
Why?
|
| Amino Acids | 1 | 2014 | 262 | 0.020 |
Why?
|
| Receptors, Histamine H1 | 1 | 2013 | 8 | 0.020 |
Why?
|
| Spectrin | 1 | 2013 | 15 | 0.020 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 139 | 0.020 |
Why?
|
| Germany | 1 | 2013 | 80 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2013 | 203 | 0.020 |
Why?
|
| Kupffer Cells | 1 | 2013 | 14 | 0.020 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2013 | 17 | 0.020 |
Why?
|
| S Phase | 1 | 2013 | 64 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 172 | 0.020 |
Why?
|
| G1 Phase | 1 | 2013 | 66 | 0.020 |
Why?
|
| Plicamycin | 1 | 2013 | 9 | 0.020 |
Why?
|
| Research Design | 1 | 2017 | 631 | 0.020 |
Why?
|
| Nucleotide Motifs | 1 | 2013 | 49 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2013 | 60 | 0.020 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 11 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1619 | 0.020 |
Why?
|
| Inhibins | 1 | 2012 | 34 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 156 | 0.020 |
Why?
|
| Wnt4 Protein | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cyclin G1 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 64 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2012 | 9 | 0.020 |
Why?
|
| Glycopeptides | 1 | 2012 | 18 | 0.020 |
Why?
|
| src Homology Domains | 1 | 2012 | 45 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 2012 | 25 | 0.020 |
Why?
|
| Receptor, EphA5 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2013 | 112 | 0.020 |
Why?
|
| Hawaii | 1 | 2012 | 26 | 0.020 |
Why?
|
| Trypsin | 1 | 2012 | 95 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 34 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 238 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 175 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2012 | 28 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2014 | 555 | 0.020 |
Why?
|
| Butyrophilins | 1 | 2012 | 28 | 0.020 |
Why?
|
| Virus Integration | 1 | 2012 | 17 | 0.020 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2012 | 6 | 0.020 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 2012 | 3 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2013 | 151 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2012 | 9 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 62 | 0.020 |
Why?
|
| Proteome | 1 | 2013 | 156 | 0.020 |
Why?
|
| HapMap Project | 1 | 2012 | 47 | 0.020 |
Why?
|
| California | 1 | 2012 | 161 | 0.020 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2012 | 24 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 206 | 0.020 |
Why?
|
| ORAI1 Protein | 1 | 2012 | 10 | 0.020 |
Why?
|
| Taiwan | 1 | 2012 | 25 | 0.020 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2011 | 4 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 2011 | 22 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Lamin Type A | 1 | 2012 | 26 | 0.020 |
Why?
|
| Ribosomes | 1 | 2012 | 122 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 41 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2012 | 173 | 0.020 |
Why?
|
| Students | 1 | 2013 | 179 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2011 | 73 | 0.020 |
Why?
|
| Cell Size | 1 | 2011 | 71 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2011 | 75 | 0.020 |
Why?
|
| Cleavage Stimulation Factor | 1 | 2011 | 1 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2011 | 85 | 0.020 |
Why?
|
| Caprylates | 1 | 2011 | 11 | 0.020 |
Why?
|
| Lysophospholipase | 1 | 2011 | 3 | 0.020 |
Why?
|
| Chemokine CXCL2 | 1 | 2011 | 16 | 0.020 |
Why?
|
| Protein Interaction Maps | 1 | 2011 | 53 | 0.020 |
Why?
|
| Azepines | 1 | 2011 | 28 | 0.020 |
Why?
|
| Duffy Blood-Group System | 1 | 2011 | 8 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 322 | 0.020 |
Why?
|
| Minichromosome Maintenance Complex Component 7 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2011 | 40 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2012 | 329 | 0.020 |
Why?
|
| Thiolester Hydrolases | 1 | 2011 | 16 | 0.020 |
Why?
|
| Creatinine | 1 | 2012 | 299 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 235 | 0.020 |
Why?
|
| Myotonin-Protein Kinase | 1 | 2011 | 1 | 0.020 |
Why?
|
| Membrane Potentials | 2 | 2003 | 442 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 325 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 825 | 0.020 |
Why?
|
| Colectomy | 1 | 2012 | 192 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 156 | 0.020 |
Why?
|
| Carrier State | 1 | 2011 | 40 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2011 | 45 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2011 | 137 | 0.020 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2011 | 9 | 0.020 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2011 | 8 | 0.020 |
Why?
|
| Acylation | 1 | 2011 | 68 | 0.020 |
Why?
|
| Propane | 1 | 2011 | 3 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2012 | 174 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 281 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2011 | 48 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 2012 | 117 | 0.020 |
Why?
|
| Podocytes | 1 | 2011 | 34 | 0.020 |
Why?
|
| Ubiquitins | 1 | 2011 | 38 | 0.020 |
Why?
|
| Consanguinity | 1 | 2011 | 73 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 20 | 0.020 |
Why?
|
| Netherlands | 1 | 2010 | 25 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2012 | 226 | 0.020 |
Why?
|
| Molecular Sequence Annotation | 1 | 2011 | 79 | 0.020 |
Why?
|
| Methionine Sulfoxide Reductases | 1 | 2010 | 1 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 297 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2010 | 33 | 0.020 |
Why?
|
| Nicotine | 1 | 2012 | 210 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2006 | 242 | 0.020 |
Why?
|
| Salmeterol Xinafoate | 1 | 2010 | 16 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2010 | 24 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 353 | 0.020 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 48 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2010 | 60 | 0.020 |
Why?
|
| Workflow | 1 | 2011 | 80 | 0.020 |
Why?
|
| Desoxycorticosterone | 1 | 2010 | 18 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 106 | 0.020 |
Why?
|
| Intellectual Property | 1 | 2010 | 3 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2010 | 21 | 0.020 |
Why?
|
| Albuterol | 1 | 2010 | 35 | 0.020 |
Why?
|
| alpha-Globins | 1 | 2010 | 1 | 0.020 |
Why?
|
| beta-Globins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Zebrafish Proteins | 1 | 2011 | 160 | 0.020 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 1 | 2010 | 3 | 0.020 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2010 | 21 | 0.020 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2010 | 17 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2010 | 15 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 50 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2010 | 79 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2010 | 55 | 0.020 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2009 | 17 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2010 | 100 | 0.020 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2010 | 48 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 116 | 0.020 |
Why?
|
| INDEL Mutation | 1 | 2010 | 33 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 41 | 0.020 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2010 | 38 | 0.020 |
Why?
|
| Chloride-Bicarbonate Antiporters | 1 | 2009 | 10 | 0.020 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Perimenopause | 1 | 2009 | 6 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Cedrus | 1 | 2009 | 2 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 128 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 41 | 0.020 |
Why?
|
| CA-19-9 Antigen | 1 | 2009 | 12 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2011 | 252 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 1 | 2009 | 2 | 0.020 |
Why?
|
| Mites | 1 | 2009 | 17 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 79 | 0.020 |
Why?
|
| alpha-Synuclein | 1 | 2009 | 24 | 0.020 |
Why?
|
| Protein Phosphatase 1 | 1 | 2009 | 31 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2009 | 147 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2010 | 95 | 0.020 |
Why?
|
| Body Composition | 1 | 2010 | 75 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 311 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2009 | 169 | 0.020 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2009 | 42 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2009 | 70 | 0.020 |
Why?
|
| Centromere Protein A | 1 | 2009 | 2 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2009 | 28 | 0.020 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2009 | 4 | 0.020 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 1 | 0.020 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 1989 | 76 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 2009 | 8 | 0.020 |
Why?
|
| Chickens | 1 | 2009 | 213 | 0.020 |
Why?
|
| Chromosome Segregation | 1 | 2009 | 35 | 0.020 |
Why?
|
| Denmark | 1 | 2009 | 19 | 0.020 |
Why?
|
| Adenine Nucleotide Translocator 2 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2010 | 254 | 0.020 |
Why?
|
| Zebrafish | 1 | 2011 | 342 | 0.020 |
Why?
|
| Femur Head | 1 | 2008 | 8 | 0.020 |
Why?
|
| Leukemia | 1 | 2011 | 328 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2009 | 94 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2009 | 137 | 0.020 |
Why?
|
| Androgens | 1 | 2009 | 179 | 0.020 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2008 | 16 | 0.020 |
Why?
|
| Cystatin M | 1 | 2008 | 2 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1506 | 0.020 |
Why?
|
| Tail | 1 | 2008 | 31 | 0.020 |
Why?
|
| RNA, Double-Stranded | 1 | 2008 | 26 | 0.020 |
Why?
|
| Collagen Type VI | 1 | 2008 | 5 | 0.020 |
Why?
|
| Health | 1 | 2008 | 29 | 0.020 |
Why?
|
| Transcription Initiation Site | 1 | 2008 | 47 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2009 | 101 | 0.020 |
Why?
|
| Cattle | 1 | 2009 | 386 | 0.020 |
Why?
|
| Genetics | 1 | 2008 | 24 | 0.020 |
Why?
|
| Allergens | 1 | 2009 | 191 | 0.020 |
Why?
|
| Pseudogenes | 1 | 2008 | 36 | 0.020 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2008 | 10 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 315 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 605 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 549 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 826 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 314 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 220 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 162 | 0.020 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2008 | 13 | 0.020 |
Why?
|
| Zinc Transporter 8 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Synovial Membrane | 1 | 2008 | 31 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 241 | 0.020 |
Why?
|
| Markov Chains | 1 | 2008 | 137 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2010 | 294 | 0.020 |
Why?
|
| Cyclin B | 1 | 2007 | 17 | 0.020 |
Why?
|
| Receptor, IGF Type 2 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Edar Receptor | 1 | 2007 | 2 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2007 | 28 | 0.020 |
Why?
|
| Overweight | 1 | 2009 | 121 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2008 | 191 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 198 | 0.020 |
Why?
|
| Diet, Atherogenic | 1 | 2007 | 14 | 0.020 |
Why?
|
| Host-Parasite Interactions | 1 | 2007 | 33 | 0.020 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 2007 | 10 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2008 | 137 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2009 | 289 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2007 | 55 | 0.020 |
Why?
|
| snRNP Core Proteins | 1 | 2007 | 9 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 262 | 0.020 |
Why?
|
| Swine | 1 | 2009 | 598 | 0.020 |
Why?
|
| Lipids | 1 | 2009 | 285 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2007 | 112 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 460 | 0.020 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2007 | 20 | 0.020 |
Why?
|
| Autophagy-Related Proteins | 1 | 2007 | 24 | 0.020 |
Why?
|
| Growth Differentiation Factor 5 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 2007 | 109 | 0.020 |
Why?
|
| Heterozygote | 1 | 2008 | 382 | 0.020 |
Why?
|
| Apelin | 1 | 2007 | 2 | 0.020 |
Why?
|
| Apelin Receptors | 1 | 2007 | 2 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2007 | 64 | 0.020 |
Why?
|
| Mitochondria, Muscle | 1 | 2007 | 27 | 0.020 |
Why?
|
| Appetite Regulation | 1 | 2007 | 7 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 286 | 0.020 |
Why?
|
| Angiotensinogen | 1 | 2006 | 5 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 126 | 0.020 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2006 | 6 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2006 | 7 | 0.020 |
Why?
|
| Guanosine Diphosphate | 1 | 2006 | 19 | 0.020 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2006 | 35 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2008 | 161 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2007 | 309 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2011 | 634 | 0.020 |
Why?
|
| Geography | 1 | 2007 | 240 | 0.020 |
Why?
|
| Models, Animal | 1 | 2008 | 286 | 0.020 |
Why?
|
| Chemokine CCL17 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2006 | 137 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 187 | 0.020 |
Why?
|
| Phenylalanine | 1 | 2006 | 36 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2006 | 26 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2006 | 41 | 0.020 |
Why?
|
| Diamond | 1 | 2006 | 2 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 350 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 615 | 0.020 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2006 | 11 | 0.020 |
Why?
|
| Fluorine | 1 | 2006 | 17 | 0.020 |
Why?
|
| Adsorption | 1 | 2006 | 54 | 0.020 |
Why?
|
| LIM Domain Proteins | 1 | 2006 | 25 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2009 | 627 | 0.020 |
Why?
|
| Stathmin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Physicians | 1 | 2013 | 707 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3639 | 0.020 |
Why?
|
| X-Rays | 1 | 2006 | 139 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2008 | 297 | 0.010 |
Why?
|
| Etoposide | 1 | 2006 | 212 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2006 | 284 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 403 | 0.010 |
Why?
|
| Respiratory Mucosa | 1 | 2006 | 90 | 0.010 |
Why?
|
| Endocytosis | 1 | 2006 | 186 | 0.010 |
Why?
|
| Isoleucine | 1 | 2005 | 19 | 0.010 |
Why?
|
| Crystallization | 1 | 2006 | 216 | 0.010 |
Why?
|
| Rats, Inbred OLETF | 1 | 2005 | 3 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 2005 | 37 | 0.010 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2005 | 37 | 0.010 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2005 | 14 | 0.010 |
Why?
|
| Protein Folding | 1 | 2007 | 295 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2005 | 30 | 0.010 |
Why?
|
| RNA, Long Noncoding | 1 | 2006 | 130 | 0.010 |
Why?
|
| Carcinogenicity Tests | 1 | 2005 | 5 | 0.010 |
Why?
|
| Cilia | 1 | 2005 | 29 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 76 | 0.010 |
Why?
|
| Osteopontin | 1 | 2005 | 48 | 0.010 |
Why?
|
| CD30 Ligand | 1 | 2004 | 2 | 0.010 |
Why?
|
| Carcinoma, Embryonal | 1 | 2004 | 2 | 0.010 |
Why?
|
| Dinucleotide Repeats | 1 | 2004 | 14 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2004 | 35 | 0.010 |
Why?
|
| Clusterin | 1 | 2004 | 14 | 0.010 |
Why?
|
| Ki-1 Antigen | 1 | 2004 | 19 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 2005 | 67 | 0.010 |
Why?
|
| Aggrecans | 1 | 2005 | 43 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 50 | 0.010 |
Why?
|
| Light | 1 | 2006 | 297 | 0.010 |
Why?
|
| Retroviridae | 1 | 2005 | 76 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 43 | 0.010 |
Why?
|
| Family | 1 | 2006 | 332 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2005 | 89 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 372 | 0.010 |
Why?
|
| Insulin-Secreting Cells | 1 | 2008 | 442 | 0.010 |
Why?
|
| fas Receptor | 1 | 2004 | 76 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2005 | 172 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2004 | 128 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2004 | 55 | 0.010 |
Why?
|
| Feedback, Physiological | 1 | 2004 | 69 | 0.010 |
Why?
|
| 1-Pyrroline-5-Carboxylate Dehydrogenase | 1 | 2004 | 2 | 0.010 |
Why?
|
| Ribosomal Proteins | 1 | 2004 | 45 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2005 | 151 | 0.010 |
Why?
|
| Aldo-Keto Reductases | 1 | 2003 | 1 | 0.010 |
Why?
|
| Cathepsin H | 1 | 2003 | 4 | 0.010 |
Why?
|
| Pyrroles | 1 | 2005 | 172 | 0.010 |
Why?
|
| Aldehyde Reductase | 1 | 2003 | 10 | 0.010 |
Why?
|
| Databases, Factual | 2 | 2002 | 1010 | 0.010 |
Why?
|
| Solute Carrier Family 22 Member 5 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2003 | 13 | 0.010 |
Why?
|
| Solute Carrier Family 12, Member 3 | 1 | 2003 | 7 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 437 | 0.010 |
Why?
|
| Alcian Blue | 1 | 2003 | 3 | 0.010 |
Why?
|
| BRCA2 Protein | 1 | 2005 | 175 | 0.010 |
Why?
|
| Anthraquinones | 1 | 2003 | 8 | 0.010 |
Why?
|
| Sodium Chloride Symporters | 1 | 2003 | 14 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 20 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2003 | 175 | 0.010 |
Why?
|
| Microtubules | 1 | 2004 | 134 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 439 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 65 | 0.010 |
Why?
|
| Prothrombin | 1 | 2003 | 19 | 0.010 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2003 | 11 | 0.010 |
Why?
|
| Transferases | 1 | 2003 | 23 | 0.010 |
Why?
|
| Dystroglycans | 1 | 2003 | 15 | 0.010 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2003 | 4 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 707 | 0.010 |
Why?
|
| Netrin-1 | 1 | 2003 | 2 | 0.010 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2003 | 3 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2004 | 274 | 0.010 |
Why?
|
| Adipocytes | 1 | 2004 | 170 | 0.010 |
Why?
|
| DNA, Antisense | 1 | 2003 | 15 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 2003 | 46 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2004 | 195 | 0.010 |
Why?
|
| Chromosomes | 1 | 2003 | 104 | 0.010 |
Why?
|
| Electroretinography | 1 | 2003 | 80 | 0.010 |
Why?
|
| Tunica Media | 1 | 2003 | 16 | 0.010 |
Why?
|
| Multiple Organ Failure | 1 | 2003 | 60 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2002 | 4 | 0.010 |
Why?
|
| 3-Phosphoinositide-Dependent Protein Kinases | 1 | 2002 | 5 | 0.010 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2002 | 29 | 0.010 |
Why?
|
| Placenta | 1 | 2004 | 191 | 0.010 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2002 | 16 | 0.010 |
Why?
|
| Behavior | 1 | 2003 | 87 | 0.010 |
Why?
|
| Protein Precursors | 1 | 2003 | 138 | 0.010 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2002 | 4 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 58 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 264 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2003 | 78 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 2003 | 90 | 0.010 |
Why?
|
| Carboxylesterase | 1 | 2002 | 10 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 2002 | 39 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2002 | 117 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 89 | 0.010 |
Why?
|
| Human Genome Project | 1 | 2002 | 22 | 0.010 |
Why?
|
| Jagged-2 Protein | 1 | 2001 | 6 | 0.010 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2001 | 13 | 0.010 |
Why?
|
| Jagged-1 Protein | 1 | 2001 | 13 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 394 | 0.010 |
Why?
|
| Interferon Regulatory Factors | 1 | 2002 | 77 | 0.010 |
Why?
|
| Aorta | 1 | 2003 | 294 | 0.010 |
Why?
|
| Heart Conduction System | 1 | 2002 | 126 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 517 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2002 | 201 | 0.010 |
Why?
|
| Receptors, Notch | 1 | 2001 | 136 | 0.010 |
Why?
|
| Myocardium | 1 | 2002 | 592 | 0.010 |
Why?
|
| Cosmids | 1 | 1993 | 22 | 0.010 |
Why?
|
| DNA Probes | 1 | 1993 | 77 | 0.010 |
Why?
|